

ASCO[®] Quality Care Symposium

DRIVING SOLUTIONS, IMPLEMENTING CHANGE

Wi-Fi

Network: quality26

no password required

PROGRAM

October 16–17, 2026

Hynes Convention Center | Boston, MA

asco.org/qcs-program

#ASCOQLTY26

ASCO[®]

AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

Contents

Committees	4
Merit Award Recipients	5
CME, MOC, and Symposium Feedback	5
Attendee Resources	6
Program at a Glance	8
Program by Day	10
Poster Directory	14

SAVE THE DATE:

2027 ASCO Quality Care Symposium

September 24-25, 2027 | Marriott Marquis Chicago | Chicago, IL | quality.asco.org

Committees

Program Committee

Ryan Nipp, MD, MBA, MPH, FASCO (Chair)

The University of Oklahoma Health, Stephenson Cancer Center

Hari Nathan, MD, PhD, FACS, FSSO (Chair-Elect)

University of Michigan

Fumiko Chino, MD, FASCO (Immediate Past Chair)

The University of Texas MD Anderson Cancer Center

Julia Close, MD, FASCO (Leadership)

ASCO

Gabriel Brooks, MD, MPH

Dartmouth

Cristiane Decat Bergerot, PhD

Oncoclinicas

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

Queen’s University

Michael Hassett, MD, MPH

Dana-Farber Cancer Institute

S. M. Qasim Hussaini, MD

University of Alabama at Birmingham

Emily Johnston, MD, MS

University of Alabama at Birmingham

Daniel H. Kwon, MD

University of California San Francisco

Christina Ahn Minami, MD, MS

Calgary

Jeffrey Peppercorn, MD, MPH

Massachusetts General Hospital

Elizabeth Horn Prsic, MD

Yale University

Stephen Schleicher, MD, MBA

Tennessee Oncology

Joseph Unger, PhD, MS

Fred Hutch Cancer Center

Courtney Williams, DrPH

University of Alabama at Birmingham

News Planning Team

Julie R. Gralow, MD, FACP, FASCO

ASCO

Joel N. Saltzman, MD, FASCO

Cleveland Clinic Taussig Cancer Center

Marcin Chwistek, MD, FAAHPM

Fox Chase Cancer Center

Julian C. Hong, MD, MS

University of California San Francisco

April K.S. Salama, MD

Duke University

Conquer Cancer®, the ASCO Foundation, Merit Award Recipients

Conquer Cancer, the ASCO Foundation, Merit Awards are designed to further promote quality clinical research by young scientists. A select number of Merit Awards are given annually to recognize outstanding research in abstracts submitted for presentation at the ASCO Quality Care Symposium.

Kim Abbegail Tan Aldecoa, MD, University of California Irvine
Oyedolapo Adedoyin Anyanwu, PhD, MS, Moffitt Cancer Center
Yajur Arya, MD, Mayo Clinic
Lauren C. Bates-Fraser, PhD, MA, American Cancer Society
John R. Bassler, MS, The University of Alabama at Birmingham
Sydney Booth, BS, BA, The University of Alabama Heersink School of Medicine
Scott Carlson, BS, Weill Cornell Medical College
Fangyuan Chen, MD, Dana-Farber Cancer Institute
Sun Choi, BSc, Princess Margaret Cancer Centre
Canan Dilay Dirican, MD, St. Mary's General Hospital and St. Clare's Health
Nickolas Dreher, MD, Columbia University Irving Medical Center
Evan Garrad, MD, University of Illinois Chicago
Sarah Ghalayini, BSc, The University of Texas MD Anderson Cancer Center
Ameish Govindarajan, MD, Cleveland Clinic
Diya Jayram, MS, University of Miami Miller School of Medicine
Ruiqi Jin, PhD, Emory University
Daniel Thomas Jones, DO, MHS, MBA, HCA Sunrise Health GME Consortium - MountainView Hospital
Taiga Komatsu, MD, Icahn School of Medicine at Mount Sinai Morningside/West
Jerry Kong, MD, The New York University Grossman School of Medicine
Manaswini Krishnakumar, MD, Saint Vincent Hospital
Chuan Angel Lu, MD, MPH, The University of Texas Southwestern Medical Center
Abigail Lustyik, RN, University of Pittsburgh School of Nursing
Johanne Dam Lyhne, MD, Vejle Hospital, University Hospital of Southern Denmark

Kaitlyn Lynch, MS, Massachusetts General Hospital
Andrew R. Maher, BSc, Queen's University
Geraldine Kordai Mould, MD, Harlem Hospital Center
Jonas M. Ndeke, MD, PhD, MPH, University of Rochester Medical Center
Ding Quan Ng, PhD, Yale School of Medicine and Yale Cancer Center
Vincent Nguyen, BS, Emory University
Afua Ofori-Darko, BS, Case Western Reserve University School of Medicine
Sandra C. Olisakwe, MSPH, University of Alabama at Birmingham
T. Anders Olsen, MD, MPP, Memorial Sloan Kettering Cancer Center
Tulsi Patel, MD, MPH, University of California San Diego
Ana Maria Teixeira Pires, PhD, Paulista School of Nursing
Yazmin Reategui-Almonacid, MD, MS, Rutgers Health, Newark Beth Israel Medical Center
Tareq Salah, MD, Yale School of Medicine
Zouina Sarfraz, MBBS, Baptist Health Herbert Wertheim Cancer Institute
Fatima Shaba, MD, Mayo Clinic School of Graduate Medical Education
Soumya Somani, BA, The University of Texas Southwestern Medical Center
Julia Stal, PhD, Dana-Farber Cancer Institute
Kian Tehranchi, MD, Beth Israel Deaconess Medical Center
Luxiga Thanabalachandran, BSc, Queen's University School of Medicine
Juncheng Tong, BS, Emory University
Kimberly J. Toomire, DO, Maine Medical Center
Haofan Yang, MPH, Emory University
Danlin Zeng, MSc, University of British Columbia

CME, MOC, and Symposium Feedback

Sessions at the ASCO Quality Care Symposium will provide Continuing Medical Education (CME) credits and Maintenance of Certification (MOC) points for physicians.

Participants should use the ASCO Meetings app or online program to:

- Claim CME credit for sessions
- Request ABIM, ABP, and/or ABS MOC points
- Provide feedback on sessions

Share feedback on your meeting experience:



Download your Certificate of Attendance at asco.org/account/profile/view-certificates.

Please visit quality.asco.org/continuing-education for more information about how to claim credit and request MOC points for Symposium sessions.

CME claims and MOC requests are due by January 19, 2027.

For questions or assistance, contact customerservice@asco.org.

Conflict of Interest Disclosure

All financial relationships reported by contributors to this activity are provided to learners prior to the start of the activity. During planning and development of the activity, relevant financial relationships were mitigated for all contributors. Relationships are considered self-held and compensated unless otherwise noted (I = Immediate family member; Inst = My Institution). Disclosures are submitted per the ASCO Policy for Relationships with Companies.

Attendee Resources

ASCO Customer Service

ASCO Customer Service, located in the Boylston Hallway on Level 3, will be available to assist you during the following times:

- Friday: 7:00 AM-5:15 PM
- Saturday: 6:45 AM-3:30 PM

ASCO Meetings Mobile App

Download or update the ASCO Meetings mobile app to:

- Search sessions and presentation details
- Create a customized agenda
- Read abstracts
- Pose questions to speakers during sessions
- Respond to presenter polls
- Claim CME/MOC credit

The program is also available on asco.org/qcs-program.

Scan the appropriate QR code below to access your device's app store:

Apple



Android



ASCO Exhibits

Visit the ASCO exhibits in the Posters and Food Room on Level 2 in Hall D on Friday from 7:00 AM to 5:15 PM and Saturday from 6:45 AM to 1:00 PM.

For some extra good vibes, a therapy dog will be visiting the ASCO exhibits on Friday during lunch. Stop by to learn more about ASCO and get some quality time with our furry friend.

Membership

- Join ASCO or renew your membership onsite and receive a 25% discount.
- Meet with Dr. Ishwaria Subbiah, Chair of the Health Services Research Committee, during lunch on Friday to share your thoughts on the future of oncology health services research.

JCO Oncology Practice

- Discover how *JCO Oncology Practice* is improving patient care through research on value, access to care, and ethics.
- Get insider tips from Editor-in-Chief Dr. Jeffrey Peppercorn during lunch on Friday.

ASCO Certified

- Learn how the ASCO Certified program can help your practice meet a single set of comprehensive standards for patient-centered care.
- Talk with the ASCO Certified team about what it takes to achieve certification and demonstrate your commitment to quality and safety.

AI Lab

- Help guide ASCO's digital experience by taking a brief survey on-site.

Innovation Demo

- Experience new Google Gemini-powered tools designed to help you get the most out of ASCO Meetings, including your on-site and post-meeting science experience. Stop by, try them out, and share your feedback.

Connections and Community

Expand your network by participating in programming designed to help you connect with other attendees and expert faculty during the Symposium. The Symposium offers a variety of networking opportunities, including an open Q&A with past Joseph Simone Award winners, a trainee and early career luncheon, poster walks, and receptions. Details, including dates, locations, and faculty can be found at asco.org/quality. All networking events are in-person only. Space is limited and available on a first-come, first-served basis.

Lost and Found

Always keep personal belongings with you during the Symposium. Lost an item or found an item? Visit the ASCO Customer Service desk in the Boylston Hallway on Level 3.

Meet Your ASCO Meetings Navigator

New for this year! Your personal guide to the meeting is here. The ASCO Meetings Navigator can help you plan your schedule, find sessions by topic or speaker, and get answers to your logistical questions.

Get started in the ASCO Meetings Mobile App or at asco.org/qcs-program (requires attendee login).

Meeting Videos, Slides, and Posters

Session recordings and downloadable slide decks will be available to all attendees within hours following each session. Posters will be available to all attendees on the morning of the presentation. To view these materials, use the ASCO Meetings mobile app or visit asco.org/qcs-program.

Nursing Room

Room 307 on Level 3 is available as a private nursing space during the meeting. A Mamava nursing pod is also available on the Plaza Level near the Prudential Plaza Entrance restrooms. Use the free Mamava app to unlock and use the pod or go to Customer Service in the Boylston Hallway to receive the code.

Policies

Important policies for this Symposium, including the Attendee Code of Conduct, are available at asco.org/quality.

Poster, Coat, and Bag Check

Complimentary poster, coat, and bag check is available on Level 3 in the Boylston Hallway. Items may not be left overnight. All unclaimed items at the end of the meeting will be turned over to the convention center.

Product Demonstrations

Explore advanced platforms leveraging deep-reasoning clinical AI, point-of-care cost transparency, AI-powered patient navigation, and virtual oncology clinical models. Each demo will be followed by dedicated one-on-one Q&A time. These demonstrations will take place on Level 2 in Hall D (Posters and Food Room).

Friday

- 12:35 PM-12:50 PM - Health Data Analytics Institute (HDAI)
- 1:25 PM-1:40 PM - Outcomes Matter Innovations

Saturday

- 11:50 AM-12:05 PM - Outcomes4Me Inc.
- 12:15 PM-12:30 PM - Color Health

Health Data Analytics Institute (HDAI): HDAI's HealthVision (hda-institute.com) helps oncologists quickly identify patients who

may need additional support, including timely Serious Illness Conversations and clearer Goals of Care planning. Embedded in the EHR, HealthVision uses deep-reasoning clinical AI to analyze notes, labs, vitals, and other patient data, then surfaces real-time risk insights with the clinical evidence behind them. For cancer centers, this means prioritizing patients with serious illness, aligning inpatient and outpatient teams, and supporting goal-concordant care throughout the course of illness.

Outcomes Matter Innovations: OMI Pulse (omimanagement.com) provides a single, point-of-care solution that bridges relevant treatments to cost for each individual patient, creating an easy-to-use, transparent system for physicians and payers.

Outcomes4Me Inc.: Outcomes4Me (outcomes4me.com) is a health tech startup on a mission to democratize healthcare and improve health outcomes. Named a Fast Company World Changing Idea and to TIME's Best Inventions list, Outcomes4Me uses AI and machine learning to help patients with cancer navigate their care and access personalized treatment information. Outcomes4Me integrates with

the NCCN Guidelines® and partners with providers to support their patients at every stage through customized education, digital symptom tracking, medication tracking to encourage adherence, clinical trial matching, and access to survivorship care plans.

Color: Color Virtual Cancer Clinic (color.com) is a single partner for accessible cancer care from screening to survivorship. Our ASCO-certified, oncologist-led virtual cancer clinic partners with employers, unions, and health plans to close screening gaps and connect patients to the right specialists at the right time—cutting time to diagnosis by 66% and closing over 75% of clinical care gaps. For partner clinics, this approach delivers faster, better-qualified referrals backed by ongoing, ASCO-aligned care coordinated with your team. Meet Color's Chief Medical Officer and see what a partnership could look like for your clinic.

Supplies and Device Charging

Water stations, note pads, and pens are located at the entrance to the General Session Room. Power strips for charging your devices are located throughout the room.

ASCO and Conquer Cancer®, the ASCO Foundation, would like to gratefully acknowledge all our donors for their generous support.

Program at a Glance

Friday, October 16

7:00 AM-8:00 AM	Complimentary Continental Breakfast
8:00 AM-9:40 AM	Oral Abstract Session A
9:40 AM-10:10 AM	Break
10:10 AM-11:25 AM	Preserving Trust as Patients, Artificial Intelligence, and Industry Redefine the Clinician's Role
11:40 AM-12:25 PM	Joseph Simone Quality Care Award
12:25 PM-1:45 PM	Poster Session A <i>With complimentary boxed lunch and product demonstrations</i>
12:35 PM-1:35 PM	Trainee and Early-Career Networking Luncheon* <i>With complimentary boxed lunch</i>
1:45 PM-2:45 PM	Rapid Oral Abstract Session A
3:00 PM-4:15 PM	Delivering Value in Everyday Oncology Care
4:15 PM-4:45 PM	Poster Walks*
4:15 PM-5:15 PM	Poster Session A (Continued) <i>With complimentary wine and cheese reception</i>

*Space is limited and is available on a first-come, first-served basis.

Program at a Glance

Saturday, October 17

7:20 AM-8:20 AM	Poster Session B <i>With complimentary continental breakfast</i>
8:20 AM-9:55 AM	Oral Abstract Session B
9:55 AM-10:25 AM	Break
10:25 AM-11:40 AM	The (Future) Role of Artificial Intelligence in Cancer Care: A Multidisciplinary Debate
11:40 AM-1:00 PM	Poster Session B (Continued) <i>With complimentary boxed lunch and product demonstrations</i>
11:45 AM-12:15 PM	Poster Walks*
12:25 PM-12:55 PM	The Quality Exchange: Open Q&A With Joseph Simone Quality Care Award Winners* <i>With complimentary boxed lunch</i>
1:00 PM-2:00 PM	Rapid Oral Abstract Session B
2:15 PM-3:30 PM	One Size Doesn't Fit All: Right-Sizing for Patient Needs, Values, and Outcomes

*Space is limited and is available on a first-come, first-served basis.

Friday, October 16

7:00 AM-8:00 AM

Complimentary Continental Breakfast

Level 2, Hall D

8:00 AM-9:40 AM

Oral Abstract Session A

Level 3, Ballroom, Salon A

Justin Michael Barnes, MD, MS—Chair
Mayo Clinic

John Kent Lin, MD—Chair
The University of Texas MD Anderson Cancer Center

Welcome of the Day

Ryan D. Nipp, MD, MBA, MPH, FASCO
The University of Oklahoma Health, Stephenson Cancer Center

Abstract 1: Affordable Care Act impact on financial well-being in commercially insured cancer patients: Credit report evidence.

First Author: Catherine R. Fedorenko, MSc

Abstract 633: The impact of FIM interventions on anxiety, depression, and quality of life: Results from nutriceare randomized controlled trial.

First Author: Juna Hatta-Langedyk

Discussion: Charles Jiang, MD, MPH
The University of Texas Southwestern Medical Center

Abstract 634: Effect of financial navigation in advanced cancer patients: Primary results from the CREDIT trial (S1912CD).

First Author: Veena Shankaran, MD, MS

Abstract 474: Implementation and effectiveness outcomes of a multi-site financial navigation intervention.

First Author: Stephanie B. Wheeler, PhD, MPH

Discussion: Courtney Williams, DrPH
University of Alabama at Birmingham

Panel Question and Answer

9:40 AM-10:10 AM

Break

10:10 AM-11:25 AM

Preserving Trust as Patients, Artificial Intelligence, and Industry Redefine the Clinician's Role

Level 3, Ballroom, Salon A

Emily Ray, MD, MPH—Chair
The University of North Carolina at Chapel Hill

Hannah Rebeccah Abrams, MD—Chair
Fred Hutch Cancer Center

Beyond the Screen: Strengthening Patient/Clinician Trust in a Digital World

Eleonora Teplinsky, MD, FASCO
Valley Health System

Can Artificial Intelligence Overcome Cognitive Bias to Improve Patient Safety: Balancing the Promise With Perils of Sycophancy

Kerin B. Adelson, MD, MS, FASCO
The University of Texas MD Anderson Cancer Center

Virtual Patient Communities for Peer Support: Benefits and Considerations

Katie Coleman
Arthur G. James Cancer Hospital - The Ohio State University

Patients With Cancer as Consumers: When Industry Bypasses Clinicians

Michael J. Hassett, MD, MPH, FASCO
Dana-Farber Cancer Institute

Panel Question and Answer

11:40 AM-12:25 PM

Joseph Simone Quality Care Award

Level 3, Ballroom, Salon A

Introduction

Ryan Nipp, MD, MBA, MPH, FASCO—Chair
The University of Oklahoma Health, Stephenson Cancer Center

The Legacy We Leave: Finding Purpose Through Caring for Patients With Blood Cancers

Areej El-Jawahri, MD, FASCO
Mass General Brigham Cancer Institute

Question and Answer

12:25 PM-1:45 PM

Poster Session A

Level 2, Hall D

With complimentary boxed lunch and product demonstrations. See pg. 14 for a full listing of posters.

12:35 PM-1:35 PM

Trainee and Early-Career Networking Luncheon

Level 3, Room 304

With complimentary boxed lunch.

1:45 PM-2:45 PM

Rapid Oral Abstract Session A

Level 3, Ballroom, Salon A

Gabriel A. Brooks, MD, MPH, FASCO—Chair
Dartmouth

Manisha Bhattacharya, MD, MBA—Chair
University of Pittsburgh

Abstract 79: Plan-level and provider-level variation in systemic therapy receipt among Medicare Advantage beneficiaries with advanced cancer.

First Author: Xin Hu, PhD

Abstract 80: Geographic disparities in access to oncologists and association with cancer mortality rates in the United States.

First Author: Qinjin Fan, PhD

Abstract 81: Reducing delays in cancer care: A mixed-methods evaluation of navigation services in a Los Angeles county safety-net system.

First Author: Jennifer Tsui, PhD, MPH

Abstract 82: Policy-associated differences in pregnancy-associated cancer mortality: Medicaid expansion and trigger-law analyses, 2018–2026.

First Author: Diya Jayram, MS

Abstract 278: Feasibility and preliminary efficacy of a culturally adapted group-based meditation intervention among Black patients with advanced cancer: A randomized controlled trial.

First Author: Dalnim Cho, PhD

Abstract 279: Oncologists' acceptance of personal financial payments from drug manufacturers and use of aggressive end-of-life care.

First Author: Aaron Philip Mitchell, MD, MPH

Abstract 2: Use and perceptions of principal illness navigation billings codes in oncology.

First Author: Gabrielle Betty Rocque, MD, FASCO

Panel Question and Answer

3:00 PM-4:15 PM

Delivering Value in Everyday Oncology Care

Level 3, Ballroom, Salon A

Hari Nathan, MD, PhD, FACS, FSSO—Chair
University of Michigan

Ryan W. Huey, MD, MS—Chair
The University of Texas MD Anderson Cancer Center

Why Should We Care About Value?

Nancy Lynn Keating, MD, MPH
Harvard Medical School

What Makes Oncology Practices Financially Sustainable in Value-Based Care?

Samyukta Mullangi, MD, MBA
Tennessee Oncology

Operationalizing Value in Your Oncology Practice

Jennifer J. Griggs, MD, MPH, FACP, FASCO
Michigan Oncology Quality Consortium

System-Level Oncology Quality Assurance: How We Do It

Thomas Varghese Jr., MD, MS, MBA, FACS
Huntsman Cancer Institute at the University of Utah

Abstract 78: Impact of a novel multi-component home and virtual supportive oncology program on acute care utilization and total health care spending.

First Author: Bridget Nicholson, PhD, AOCNP

Panel Question and Answer

4:15 PM-4:45 PM

Poster Walks

Level 2, Hall D

See pg. 14 for a full listing of posters.

Jeffrey M. Peppercorn, MD, MPH, FASCO—Poster Walk Leader
Massachusetts General Hospital

Charles Jiang, MD, MPH—Poster Walk Leader
The University of Texas Southwestern Medical Center

4:15 PM-5:15 PM

Poster Session A (Continued)

Level 2, Hall D

With complimentary wine and cheese reception. See pg. 14 for a full listing of posters.

Saturday, October 17

7:20 AM-8:20 AM

Poster Session B

Level 2, Hall D

With complimentary continental breakfast. See pg. 29 for a full listing of posters.

8:20 AM-9:55 AM

Oral Abstract Session B

Level 3, Ballroom, Salon A

Elizabeth Horn Prsic, MD—Chair
Yale University

Kaitlyn Lapen, MD—Chair
Memorial Sloan Kettering Cancer Center

Welcome of the Day

Hari Nathan, MD, PhD, FACS, FSSO
University of Michigan

Abstract 276: Cancer-related fatigue as partial mediator of the effect of a remotely delivered exercise intervention on health-related quality of life: Phase II randomized trial.

First Author: Paulo Gustavo Bergerot, MD

Abstract 670: EMPOWER: Exercise and movement to promote our patients with gynecologic cancer to enhance resiliency—A pilot study.

First Author: Stephanie Cham, MD, MS

Discussion: To be determined

Abstract 277: Pilot randomized trial of a scalable, multi-component mHealth app combining cognitive behavioral therapy for pain (pain-CBT) and opioid support for patients with advanced cancer.

First Author: Desiree Rachel Azizoddin, PsyD

Abstract 380: Perceptions of nursing staffing needs for remote symptom monitoring with patient-reported outcomes before and after program implementation.

First Author: Nicole Lynn Henderson, PhD, MPH

Discussion: Monika K. Krzyzanowska, MD, MPH, FRCPC, FASCO
Sunnybrook Health Sciences Centre

Panel Question and Answer

9:55 AM-10:25 AM

Break

10:25 AM-11:40 AM

The (Future) Role of Artificial Intelligence in Cancer Care: A Multidisciplinary Debate

Level 3, Ballroom, Salon A

Fumiko Chino, MD, FASCO—Chair
The University of Texas MD Anderson Cancer Center

Anai Kothari, MD, MS—Chair
Medical College of Wisconsin

Multidisciplinary Debate

Patient Advocate Perspective

Brian Alan Jones, BCPA, CCHW
ZERO Prostate Cancer

Clinician/Researcher Perspective

Ravi Bharat Parikh, MD, MPP
Winship Cancer Institute of Emory University

Clinician/Researcher Perspective

Andrew M. Ibrahim, MD, MSc
University of Michigan

Frontline Workflow Perspective

Michael Anne Kyle, PhD
Perelman School of Medicine, University of Pennsylvania

Researcher Perspective

Roy Perlis, MD, MSc
Massachusetts General Hospital

Panel Question and Answer

11:40 AM-1:00 PM

Poster Session B (Continued)

Level 2, Hall D

With complimentary boxed lunch and product demonstrations. See pg. 29 for a full listing of posters.

11:45 AM-12:15 PM

Poster Walks

Level 2, Hall D

See pg. 29 for a full listing of posters.

To be determined—Poster Walk Leader

Stephen M. Schleicher, MD, MBA, FASCO—Poster Walk Leader
Tennessee Oncology

12:25 PM-12:55 PM

The Quality Exchange: Open Q&A With Joseph Simone Quality Care Award Winners

Level 3, Room 304

With complimentary boxed lunch.

Areej El-Jawahri, MD, FASCO
Mass General Brigham Cancer Institute

Ethan Basch, MD, MSc, FASCO
The University of North Carolina at Chapel Hill

Robin Yabroff, PhD, MBA, FASCO
American Cancer Society

1:00 PM-2:00 PM

Rapid Oral Abstract Session B

Level 3, Ballroom, Salon A

Daniel H. Kwon, MD—Chair
University of California San Francisco

Erika Moen, PhD—Chair
Geisel School of Medicine at Dartmouth

Abstract 671: Use of a tailored clinical intervention for head and neck cancer (HNC) survivors: Findings from the HN-STAR trial (WF-1805CD).

First Author: Talya Salz, PhD

Abstract 672: Large language models to support oncology symptom telephone triage: A retrospective pre-implementation evaluation.

First Author: Luxiga Thanabalachandran, BSc

Abstract 673: Ambient artificial intelligent scribes in oncology: Impact on clinician experience and documentation burden.

First Author: Abigail Baldwin-Medsker, MBA, MSN, RN

Abstract 674: Participant adherence to standard-of-care (SOC) cancer screening after multi-cancer early detection (MCED) testing: Results from PATHFINDER 2.

First Author: Gretchen Stipec, MD, MBA

Abstract 475: Accrual speed and characteristics of phase III U.S. cancer clinical trials with frequently used biomarkers in eligibility criteria.

First Author: Fangyuan Chen, MD

Abstract 280: Examining key sociodemographic characteristics of adolescents and young adults with advanced cancer: A secondary analysis of the Promoting Resilience in Stress Management for Advanced Cancer (PRISM-AC) randomized clinical trial.

First Author: Alison O'Daffer, MS

Abstract 83: Neighborhood-level social cohesion as a predictor of colonoscopy screening uptake in US adults: A cross-sectional study using All of Us research program data.

First Author: Geraldine Kordai Mould, MD

Panel Question and Answer

2:15 PM-3:30 PM

One Size Doesn't Fit All: Right-Sizing for Patient Needs, Values, and Outcomes

Level 3, Ballroom, Salon A

Cristiane Decat Bergerot, PhD, MS, FASCO—Chair
Oncoclinicas&Co

Angela Marie Feraco, MD—Chair
Dana-Farber Cancer Institute

From Fragmentation to Coordination: Systems-Level Care Solutions in Adolescent and Young Adult and Early-Onset Patients With Cancer

Thejal Srikumar, MD, MPH

Yale School of Medicine

Precision in the Operating Room: Delivering High-Value, Personalized Surgical Cancer Care

Christina Ahn Minami, MD, MS, FACS

University of Calgary

Beyond the Guidelines: Caring for Older Adults With Cancer

Mina S. Sedrak, MD, MS, FASCO

UCLA Health Jonsson Comprehensive Cancer Center

Right-Sizing My Care: The Patient Perspective

Julia Maués, MA

GRASP

Abstract 378: Building the academic-community hybrid: Coordinating complex care across the academic and community settings to improve patient experience and reduce geographic barriers.

First Author: Daniel Aaron Roberts, MD

Abstract 379: Patient-reported quality-of-life outcomes with pharmacokinetically dose optimized low-dose nilotinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the randomized phase II NILLOW trial.

First Author: Deepak Garg, DM

Panel Question and Answer

Poster Session Directory

Friday, October 16

12:25 PM-1:45 PM and 4:15 PM-5:15 PM

Poster Session A

Level 2, Hall D

Posters by Topic

Cost, Value, and Policy

- Cost and Cost-Effectiveness of Care: A1-A3, A5-A24, B1-B13
- Guideline-Concordant Care Initiatives: B14-B24, C1-C3
- Integrating Non-Oncology Clinicians Into Care Delivery: C4
- Organizational and Operational Issues: C5-C15
- Team-Based Approaches to Care Delivery: C16-C21
- Value-Based Models of Care: C22, C23, D1-D4

Palliative and Supportive Care

- Caregivers: D5-D10
- End-of-Life Care: D11-D21
- Integrative Oncology: D22-D24, E1-E4
- Late and Long-Term Adverse Effects: E5-E8
- Palliative Care: E9-E24, F1-F7
- Psychosocial, Spiritual, Cultural, and Financial Support Services: F8-F23, G1-G7
- Survivorship Care Needs: G8-G17
- Toxicity Prevention, Assessment, and Management: G18-G24, H1, H2, H5, H6

Quality, Safety, and Implementation Science

- Application of Quality Improvement Tools: H7-H24
- Implementation Science: J1-J23, K1-K3
- Patient Safety: K4-K20
- Prospective Risk Assessment and Risk Reduction: K21-K24, L1-L8
- Quality Improvement Research: L9-L24, M1-M23, N1-N11, N13-N24, P1-P16
- Standardization and Technology Efforts to Improve Safety: Q1-Q5

Survivorship

- Care Coordination, Cost, and Education: Q6-Q9
- Chronic Anticancer Therapy: Q10, Q11
- Health Promotion: Q12, Q13, R1-R7
- Late- and Long-Term Effects/Comorbidities: R8-R16, S1-S3
- Psychosocial Issues: S4-S8, S14
- Secondary Malignancies: S15, S16

Board A1 Abstract 3: NET healthcare costs and quality of care: Global trends 2019–2025.
First Author: Elyse Gellerman, MHS

Board A2 Abstract 4: Democratizing cellular therapeutics: A review of emerging CAR-T trials in India in the context of high-cost U.S. models.
First Author: Sanchit Mehta, MBBS

Board A3 Abstract 5: Mitigating environmental toxicity & institutional economic burden: A life cycle assessment of risk-stratified breast cancer screening pathways.
First Author: Weijie Pan, PhD

Board A5 Abstract 7: Association between dental insurance coverage and financial well-being of patients with head and neck cancer.
First Author: Yunhan Wang

Board A6 Abstract 8: Catastrophic cost exposure for oral anticancer therapy under marketplace HDHPs.
First Author: Suhita Kodali, BA

Board A7 Abstract 9: Cost-effectiveness of CHALLENGE-based supervised exercise to reduce colon cancer progression and mortality in the US.
First Author: Ding Quan Ng, PhD, BScPharm

Board A8 Abstract 10: Molecular testing and cost of care in patients with early-stage resected non-small cell lung cancer (NSCLC).
First Author: Coral Olazagasti, MD

Board A9 Abstract 11: Patterns of cost-sharing for patients prescribed osimertinib in an integrated health system.
First Author: Jenny Zhao, MD

Board A10 Abstract 12: Cost-effectiveness analysis of remote symptom monitoring interventions for adjuvant endocrine therapy in early-stage breast cancer.
First Author: Xin Hu, PhD

Board A11 Abstract 13: Modeled cost of severe adverse events of first line amivantamab plus lazertinib or osimertinib plus chemotherapy in patients with treatment naïve EGFR-mutated advanced NSCLC.
First Author: Alexander I. Spira, MD, PhD, FACP, FASCO

Board A12 Abstract 14: Projected impact of biosimilar entry on the cost-effectiveness of immune checkpoint inhibitors across tumor types: A multi-indication threshold analysis.
First Author: Mariam Bari

Board A13 Abstract 15: Potential utilization and projected cost savings of Baveno VII–guided selective endoscopy prior to systemic therapy in unresectable hepatocellular carcinoma: A real-world Veterans Health Administration experience.
First Author: Christopher Huy Doan, MD

Board A14 Abstract 16: De-escalation of surveillance imaging in low-risk cancer survivors: A systematic review and meta-analysis of survival, cost, and false-positive outcomes.
First Author: Mariam Bari

Board A15 Abstract 17: Rebalancing cancer care financing: Resource utilization patterns from the COST-FIN trial in Nigeria.
First Author: Dorcas Ebekue, BSc

Board A16 Abstract 18: Real-world health care resource utilization and economic costs of antibody drug conjugate (ADC) treated solid tumor patients.
First Author: Sara M. Tolaney, MD, MPH, FASCO

Board A17 Abstract 19: A SEER-Medicare microsimulation model for evaluating care trajectories and long-term outcomes in metastatic non-small cell lung cancer.
First Author: Boshen Jiao, PhD, MPH

Board A18 Abstract 20: Implementing geolocation and multidisciplinary team coordination in an oncology unit: A quality improvement approach to inpatient care efficiency.
First Author: Anas Bizanti, MD

Board A19	Abstract 21: Post-dose dexamethasone for prevention of tarlatamab-associated CRS and ICANS: A single-center experience. First Author: Kiera Roubal	Board B9	Abstract 35: Reducing chemotherapy at the end of life and inpatient chemotherapy utilization using a novel scoring algorithm. First Author: Aarti Sonia Bhardwaj, MD
Board A20	Abstract 22: Defining value-based PLCom2012 eligibility thresholds for low-dose CT lung cancer screening. First Author: Omer Sayed Ashruf, MD	Board B10	Abstract 36: Impact of a 10% dose-rounding policy on oncology drug waste and cost avoidance in a community infusion center. First Author: Gurneel Dhanesar, MD
Board A21	Abstract 23: Optimizing tarlatamab delivery: Effects on length of stay and healthcare resource utilization. First Author: Ratika Dogra, MD, MBBS	Board B11	Abstract 37: Cost implications of broad genomic profiling among Medicare patients with metastatic lung cancer. First Author: Akintunde Aremu, MBA
Board A22	Abstract 24: National and state-level variation and temporal trends in the cost of five CMS-negotiated oral cancer drugs in Medicare Part D, 2014–2023. First Author: Padmanayakege Chamithra Dilshani Rupasinghe, MD, MPH	Board B12	Abstract 38: Underutilization of billing for longitudinal care in oncology using code G2211. First Author: Satish Stephen Maharaj, MBBS
Board A23	Abstract 25: Exclusivity-defining patents for FDA Orange Book-listed oral oncology drugs: Clinical evidence and Medicare spending. First Author: Sarah Ghalayini, BSc	Board B13	Abstract 39: Value of pretreatment DPYD genotyping in gastrointestinal oncology: An analysis of cost avoidance and healthcare utilization. First Author: Aaron Bertolo, MD
Board A24	Abstract 26: Correlation between somatic and point-of-care germline testing in patients with newly diagnosed pancreatic cancer. First Author: Amin Benyounes, MD	Board B14	Abstract 40: Biomarker matched biologic use in patients with metastatic colorectal cancer (mCRC). First Author: Tareq Salah, MD
Board B1	Abstract 27: Salvaging infusion center costs: A QI initiative. First Author: Ogechi Ogonnaya Agogbuo, MD	Board B15	Abstract 41: Enhanced care for older adults: A three-pronged quality improvement project in community and specialty medical oncology. First Author: Armida Parala-Metz, MD
Board B2	Abstract 28: Systemic anti-cancer therapy and healthcare utilization cost at end of life among older cancer patients. First Author: Kerin B. Adelson, MD, MS, FASCO	Board B16	Abstract 42: Exploring ordering patterns in initial monoclonal gammopathy workup. First Author: Staci Keene
Board B3	Abstract 29: 340b hospital participation and initial oncology treatment choice. First Author: Nina Galanter, PhD	Board B17	Abstract 43: Value of whole-exome sequencing-based TMB assessment in reducing misdirected pembrolizumab spend across advanced solid tumors. First Author: Niyati Shah, MPH
Board B4	Abstract 30: Financial toxicity among cancer patients with limited English proficiency. First Author: Scott Carlson, BS	Board B18	Abstract 44: Trends in primary endocrine therapy utilization among patients with early-stage ER+/HER2– breast cancer who do not undergo surgery: A National Cancer Database analysis. First Author: Christopher Fiorina
Board B5	Abstract 31: Balancing cost and cure in frontline diffuse large B-cell lymphoma: A comparative modeling study of emerging treatment strategies. First Author: Garrett Bourne, MD	Board B19	Abstract 45: Implementing DPYD testing prior to treatment with fluoropyrimidines at Lahey Clinic. First Author: Zeina Kayali, MD
Board B6	Abstract 32: Risk-based financial navigation targeting among U.S. cancer survivors before the Medicare Part D out-of-pocket cap: MEPS 2017–2023. First Author: Vaishali Aggarwal, MBBS	Board B20	Abstract 46: Implementation of a guideline-aligned lung cancer screening questionnaire in a resident run internal medicine clinic. First Author: Amit Krishnan, MD
Board B7	Abstract 33: National drug cost analysis across the classical Hodgkin lymphoma treatment continuum: The brentuximab and checkpoint inhibitor era. First Author: Lauren Fang, MD	Board B21	Abstract 47: Detection without survivorship: A quality gap analysis of endocrine toxicity surveillance in landmark gastrointestinal immune checkpoint inhibitor trials. First Author: Shashank Sajjan Mungasavalli Gnanesh
Board B8	Abstract 34: Financial toxicity among patients engaged in clinical research: Prevalence, disparities, and variation by study type. First Author: Scott Carlson, BS	Board B22	Abstract 48: Pathways without a price tag: Leveraging the NCCN Categories of Preference to meet ASCO Certified Pathway Standard. First Author: Navid Sadeghi, MD, MSPH, FACP

Board B23	Abstract 49: Adherence to clinical surveillance guidelines in von Hippel-Lindau (VHL) disease: Evaluating the impact of a provincial coordinated care model in Canada. First Author: Dawson Born, MD	Board C12	Abstract 62: Research training and career intentions among medical oncology fellows amid US federal funding shifts: A national cross-sectional study. First Author: David D. Chism, MD, MS
Board B24	Abstract 50: Economic burden of guideline-discordant cervical cancer screening among commercially insured women age 15 to 20 years. First Author: Hanwen Zhang, MS	Board C13	Abstract 63: What patients are told about health data sharing: A national review of privacy notices at NCI-Designated Comprehensive Cancer Centers. First Author: Sydney Haerim Kang, MPH
Board C1	Abstract 51: Broad genomic profiling, targeted therapy receipt, and overall survival among patients with metastatic non-squamous non-small cell lung cancer. First Author: Sida Huang, BSc, MPH	Board C14	Abstract 64: Impact of 2026 Medicare coding changes on access to care in a multi-site metropolitan cancer center: A comparison of prior authorization timing. First Author: William Chun-Ying Chen, MD
Board C2	Abstract 52: Federal housing assistance, stage at diagnosis, treatment receipt, and survival for patients with pancreatic cancer in the US. First Author: Amanda L. Blackford, ScM	Board C15	Abstract 65: Rural-urban divide for cancer in Medicare: An analysis of utilization and outcomes in fee-for-service Medicare in 2023. First Author: T. Anders Olsen, MD, MPP
Board C3	Abstract 53: Influenza vaccination uptake and influenza infection burden among patients with newly diagnosed hematologic malignancies: A national Epic Cosmos analysis. First Author: Varshini Srinivasan, MBBS	Board C16	Abstract 66: One team, one visit: Reducing time to treatment through a multidisciplinary clinic in rectal cancer. First Author: Ashlee Winslow, MD, MS
Board C4	Abstract 54: Vertical integration of radiation oncologists and use of stereotactic body radiation therapy for bone metastases in Medicare beneficiaries. First Author: Mokshad Gaonkar, MS	Board C17	Abstract 67: Development of clinical criteria for primary oncology service involvement among solid tumor inpatients at MD Anderson Cancer Center. First Author: Kerin B. Adelson, MD, MS, FASCO
Board C5	Abstract 55: Preparedness on paper vs. in practice: Emergency and climate resilience among US cancer centers. First Author: Emily Hayes Wood, BA, MPH	Board C18	Abstract 68: Implementation of genetic counseling recommendations in an MTB setting. First Author: Whitney Rose Swain, BSc
Board C6	Abstract 56: Observations in length of stay and clinical outcomes when transitioning from medical oncology–led to hospital medicine–led inpatient services. First Author: Stav Dor Cullum, MD	Board C19	Abstract 69: Implementation needs for expanding oncologist-led germline genetic testing: A qualitative analysis of patients and clinicians. First Author: Vicky Ro, MD, MPH
Board C7	Abstract 57: Evaluating chemotherapy allocation during a severe drug shortage of carboplatin. First Author: Eric Blackstone, PhD	Board C20	Abstract 70: PROGRESS: Implementing a hybrid decentralized clinical trial to advance precision oncology and improve cancer care quality and equity across North Carolina oncology practices. First Author: Meghan McGonagle, PharmD
Board C8	Abstract 58: Facility-year sarcoma radiotherapy volume and overall survival in extremity soft tissue sarcoma. First Author: Johnathan Zeng, MD	Board C21	Abstract 71: Centralized, AI-assisted pre-screening to scale clinical trial eligibility review across an NCI-Designated Comprehensive Cancer Center. First Author: Alizabeth Ulin, MS
Board C9	Abstract 59: Hospital and physician level vertical integration trend in the United States in oncology practice, 2016-2022. First Author: Ruoxi Teng, MS	Board C22	Abstract 72: Value-based care: Insights from a survey of patients with cancer in the United States. First Author: Kimberly Brunisholz
Board C10	Abstract 60: Relocation of post-treatment scalp cooling to improve infusion chair capacity: A quality improvement pilot. First Author: Iris Zhi, MD, PhD	Board C23	Abstract 73: Cross-organizational implementation of weight-based checkpoint inhibitor dosing in a value-based care framework. First Author: Jody S. Garey, PharmD
Board C11	Abstract 61: Hospital–PCP integration and cancer care delivery among Medicare patients with cancer. First Author: Yousef Chavehpour, PhD	Board D1	Abstract 74: Could outpatient rehabilitation support success in value-based care models? Evidence from Enhancing Oncology Model (EOM) episodes. First Author: Kelley C. Wood, PhD, MS
		Board D2	Abstract 75: Comprehensive analysis: SNF and inpatient correlation in terms of cost drivers and implications for VBC model design. First Author: Divya Deepak, MS

Board D3	Abstract 76: Evaluating the value framework of antibody-drug conjugates in metastatic solid tumors: A methodological analysis of ESMO-MCBS v2.0 and surrogacy quality. First Author: Sara Gauthier	Board D16	Abstract 292: Racial/ethnic and urban-rural disparities in place of death and hospice utilization among patients dying from biliary tract cancers: A national CDC WONDER analysis (2003–2020). First Author: Tapan Ramesh Giri, MBBS
Board D4	Abstract 77: Patient-reported symptoms as early signals of high-cost chemotherapy episodes in GI cancer. First Author: Elizabeth Davis, MSPH	Board D17	Abstract 293: Outcomes following biliary decompression interventions for jaundiced patients with malignant intrahepatic obstruction from metastatic cancer. First Author: Tessa Crilley
Board D5	Abstract 281: Inclusion of caregivers in state comprehensive cancer control plans in the United States: A content analysis. First Author: Tess Thompson, PhD	Board D18	Abstract 294: Quality of cancer care for telehealth users using QOPI-adapted hospice at end-of-life measures. First Author: Swetha Kota
Board D6	Abstract 282: Modification of baseline caregiver anxiety response to an 8-week supportive care intervention for rural cancer caregivers. First Author: Erin E. Kent, PhD, MS	Board D19	Abstract 295: Surviving longer, planning later? Unmet needs of end of life planning among long-term survivors with advanced NSCLC. First Author: Kirsten Glynn, MPH
Board D7	Abstract 283: Estimating informal caregiving time among older U.S. cancer survivors by health-related quality of life using the Health and Retirement Study. First Author: Juncheng Tong, BS, MS	Board D20	Abstract 296: National trends in place of death among patients with bladder cancer in the United States, 1999–2020. First Author: Bibek Shrestha, MD
Board D8	Abstract 284: Perceptions, knowledge, and attitudes toward do-not-resuscitate (DNR) and do-not-intubate (DNI) orders among caregivers of cancer patients in Lebanon: A cross-sectional study. First Author: Nicole Charbel, MD	Board D21	Abstract 297: Timing of claims-based specialist palliative care team billing and end-of-life healthcare costs among patients with stage IV pancreatic cancer in Japan. First Author: Naoki Sakakibara, PhD
Board D9	Abstract 285: Improving cancer caregiver support through navigation training. First Author: Ashley Bowen, RD, MS, MSc	Board D22	Abstract 298: Skin-related quality of life following oncology-trained aesthetician services in a diverse, underserved breast cancer population: A multi-institutional study. First Author: Soumya Somani, BA
Board D10	Abstract 286: Caregiver-rated performance status as a missing clinical signal: Implications for anticancer treatment, NLR, and outcomes in hospitalized solid tumor patients. First Author: Holly Gwen Prigerson, PhD	Board D23	Abstract 299: Implementation and early outcomes of a statewide oncology primary palliative care training program. First Author: Natalia Simon, MA, MBA
Board D11	Abstract 287: Implementation of medical aid in dying as an end-of-life option informed by a physician survey. First Author: Abigail Baldwin-Medsker, MBA, MSN, RN	Board D24	Abstract 300: Patient experiences with digital supportive care interventions during breast radiation therapy: A mixed-methods analysis from the PRO-ACTIVE pilot study. First Author: Chelsea Blanes, MPH
Board D12	Abstract 288: Trends in palliative care utilization, life-sustaining interventions, and hospital costs among patients with terminal lung cancer through the COVID-19 pandemic: A National Inpatient Sample analysis (2018-2023). First Author: Mohammed Oyiwa Musa, MD	Board E1	Abstract 301: Identifying gaps in cancer pain management among oncology clinicians: A needs assessment to inform a targeted quality improvement intervention. First Author: Johnathan Yao, MD, MPH
Board D13	Abstract 289: Utility (or futility) of inpatient chemotherapy in patients with advanced solid organ cancers near end of life (FOCUS-EOL). First Author: Adeel Arshad, MBBS	Board E2	Abstract 302: Protein-energy malnutrition, inpatient mortality, and resource use in gastrointestinal cancer hospitalizations. First Author: Azza Sarfraz, MBBS
Board D14	Abstract 290: Prognostic significance of unplanned admissions among patients with cancer. First Author: Lucy Gao, MD	Board E3	Abstract 303: Non-pharmacological pain care after surgery in cancer. First Author: Cindy Tofthagen, PhD, ARNP
Board D15	Abstract 291: Serious illness conversations and end-of-life healthcare utilization among patients with Chinese language preference and advanced cancer. First Author: Adrienne Kavita Yang, MD	Board E4	Abstract 304: Substance use disorder associated with acupuncture use among cancer patients with chemotherapy-induced peripheral neuropathy. First Author: Chuan Angel Lu, MD, MPH

Board E5	Abstract 305: Incidence and treatment patterns of radiation cystitis following pelvic malignancy: A multi-institutional retrospective analysis. First Author: Julia Fan	Board E19	Abstract 319: The impacts of integrating palliative care in a community oncology practice: A retrospective cohort study. First Author: Navjot Kaur, BS
Board E6	Abstract 306: Real-world healthcare utilization and supportive care burden of CAR T-cell therapy versus bispecific antibodies in diffuse large B-cell lymphoma (DLBCL). First Author: Saurav Das, MD	Board E20	Abstract 320: Timing of palliative care consultation in advanced cancer: A systematic review. First Author: Ban Al-Abayechi, MD, MBChB
Board E7	Abstract 307: Temporal patterns of radiation cystitis development: Implications for post-treatment surveillance protocol. First Author: Julia Fan	Board E21	Abstract 321: Symptom monitoring program linked to electronic referrals (SyMPLER): A single-arm pilot feasibility study of remote symptom monitoring with palliative care self-referral. First Author: Julia L. Agne, MD
Board E8	Abstract 308: Real-world assessment of late hematologic toxicities among patients with prostate cancer treated with PARP inhibitors: A global federated health research network analysis. First Author: Arshi Syal, MD	Board E22	Abstract 322: Palliative care integration and end-of-life outcomes in biomarker-selected metastatic non-small cell lung cancer. First Author: Carley Mitchell, MD
Board E9	Abstract 309: Timing of palliative care integration and acute care utilization in metastatic prostate cancer: A quality improvement analysis. First Author: Ekaterina Proskuriakova, MD	Board E23	Abstract 323: Determinants of palliative care (PC) access and early referral in pancreatic ductal adenocarcinoma (PDAC). First Author: Cesar Burgos-Jimenez, MD
Board E10	Abstract 310: Improving palliative care integration for veterans with metastatic lung cancer at Orlando VA Medical Center (OVAMC). First Author: Faris Alamin, MD	Board E24	Abstract 324: Disparities in palliative care and advance care planning by race/ethnicity and language preference in patients with advanced GI cancer. First Author: Constanza Menendez Alurralde, MD, MS
Board E11	Abstract 311: Palliative care referral timing and end-of-life outcomes in multiple myeloma. First Author: Muhammad Haseeb Khan, MD	Board F1	Abstract 325: Understanding factors associated with knowledge of palliative care among U.S. cancer survivors: Findings from a nationally representative survey. First Author: Oluwafemifola Oyedeji, MD, PhD, MPH
Board E13	Abstract 313: Impact of hospital type on hospice disposition in young-onset gastrointestinal cancers. First Author: Mrinalini Ramesh, DO	Board F2	Abstract 326: Factors associated with the decision to change chemotherapy treatment for patients with metastatic cancer. First Author: Michael J. Hassett, MD, MPH, FASCO
Board E14	Abstract 314: Understanding the impact of state cannabis policies on cancer pain management practices and outcomes. First Author: Devon Check, PhD	Board F3	Abstract 327: Understanding the symptom burden and health-related quality of life among black patients with multiple myeloma: A retrospective analysis of patient-reported data. First Author: Osborn Owusu Ansah, BSN, BN
Board E15	Abstract 315: Palliative care team perspectives on opioid education for patients with cancer: A mixed-methods study. First Author: Nicole Dussault	Board F4	Abstract 328: Access to guideline-recommended supportive oncology medications in Medicare Part D. First Author: Yixin Tang, MEd
Board E16	Abstract 316: Early palliative care integration and survival outcomes in metastatic colorectal cancer: A propensity-matched analysis of a national real-world cohort. First Author: Nnamdi Joseph Omenuko, MD	Board F5	Abstract 329: Advancing serious illness communication in oncology: A scalable psychologically informed educational model with longitudinal case-based learning. First Author: Leah Beth Rosenberg, MD
Board E17	Abstract 317: Inpatient palliative care (PC) consultation in hospitalized patients with cancer. First Author: Kolton Kardokus, DO	Board F6	Abstract 330: Opioid prescribing patterns and toxicology testing in patients with cancer within a palliative care clinic at an NCI-designated cancer center. First Author: Tristaan Haddad
Board E18	Abstract 318: Frequent unplanned hospitalizations and missed palliative care consultation among patients with solid tumors: A quality improvement analysis. First Author: Smriti Nair, MD	Board F7	Abstract 331: Developing a novel curriculum in medical cannabis for the supportive oncology context: Insights from palliative medicine program directors. First Author: Samantha Kumarasena, MD

Board F8	Abstract 332: Prevalence of social isolation and associated factors in adult cancer patients: Cross-sectional evidence from a tertiary-care cancer center in India. First Author: Prabuddha Basu, MBBS	Board F21	Abstract 345: Existential challenges and coping strategies among patients with myeloid cancers who face high-stakes treatment decision-making. First Author: Rachel Rodenbach, MD, MS
Board F9	Abstract 333: Cumulative social isolation burden and overall survival in patients with cancer: a population-based cohort study. First Author: Danlin Zeng, MSc	Board F22	Abstract 346: From grant to clinic: Outcomes and sustainability of an integrated psychosocial program in community oncology. First Author: Alexandria Muench
Board F10	Abstract 334: Social participation and material financial hardship among adult cancer survivors in Utah. First Author: Mary Killela, PhD, BSN	Board F23	Abstract 347: Trends in leukemia mortality with concurrent ischemic heart disease in the United States, 1999-2024: A population-based CDC WONDER analysis. First Author: Krishna Sai Kiran Sakalabaktula, MD
Board F11	Abstract 335: Early assessment of pre-radiation therapy financial toxicity in prostate cancer from the navigator-assisted hypofractionation (NAVAH) clinical trial. First Author: Fara Dayani, MD	Board G1	Abstract 348: Non-medical side effects of cancer: Patient perspectives on employment, identity, and basic needs. First Author: Mia Sanati, PhD, MA
Board F12	Abstract 336: Gaps in culturally concordant cancer care for Hindu adults and their family caregivers. First Author: Rushil Virendra Patel, MD	Board G2	Abstract 349: Feasibility of credit union-based “Life Over Debt” cancer-related financial hardship intervention. First Author: Courtney Williams, DrPH
Board F13	Abstract 337: Coping trajectories among early phase cancer clinical trial (EPCT) participants. First Author: Anh B. Lam, DO, MBA	Board G3	Abstract 350: Impact of an EMR-integrated, screening-based oncology financial counseling program. First Author: Nickolas Dreher, MD
Board F14	Abstract 338: Factors influencing attendance of peer support interventions for Black women with endometrial cancer in the Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence (SISTER) study. First Author: Julianna Glaser Alson, MPH	Board G4	Abstract 351: Depressive symptoms, financial barriers, and access to care among U.S. cancer survivors: A nationally representative analysis. First Author: Eduardo Reyes, MD
Board F15	Abstract 339: Screening for distress and sources of distress in parents with advanced cancer and their coparents. First Author: Sujin Ann-Yi, PhD	Board G5	Abstract 352: Implementing a learning collaborative model to improve financial navigation in oncology. First Author: Kristen McNiff Landrum, MPH, DPH
Board F16	Abstract 340: Impact of financial navigation and copay assistance on treatment adherence, financial distress, and quality of life in oral anticancer therapy. First Author: Mahboob Younus Shaik, MD	Board G6	Abstract 353: Community-based support and cancer-related loneliness in rural outpatient oncology: A comparative cross-sectional study. First Author: Mark Gao
Board F17	Abstract 341: Long-term impact of clinic-led social programming in pediatric oncology: Perspectives from young adult survivors and healthcare providers. First Author: Jennifer Costa, PhD, BSN, MSN	Board G7	Abstract 354: Gaps in psychosocial care delivery for early-onset gastrointestinal cancer: Distress screening and referral patterns from a single institution. First Author: Wesley Dean Boland, MD
Board F18	Abstract 342: The heart of the mission: Scaling supportive oncology care through a centralized multidisciplinary collaboration. First Author: Timothy Steinhoff	Board G8	Abstract 355: Hormone therapy prescribing for iatrogenic menopause after definitive chemoradiation for squamous cell cervical cancer: A retrospective review. First Author: Morgan Sydney Levy, MD, MPH
Board F19	Abstract 343: Introducing the Colorado Cancer CARE (Colorado all-payer claims data, Central Cancer Registry, and credit report) linkage. First Author: Helen M. Parsons, PhD, MPH	Board G9	Abstract 356: A qualitative study of barriers and facilitators to high-tech augmentative and alternative communication tools to enhance communication in patients with tumor-related aphasia. First Author: John Yohan Rhee, MD, MPH
Board F20	Abstract 344: Feasibility study of virtual reality support groups for patients with early onset cancer. First Author: Thejal Srikumar, MD, MPH	Board G10	Abstract 357: Differences in cancer-related employment disruptions between cancer survivors & caregivers. First Author: Robert Besaw, PhD

- Board G11 Abstract 358: Preventive care in the age of immunotherapy: Colorectal cancer screening among patients with metastatic melanoma.**
First Author: Justine Elshama
- Board G12 Abstract 359: Unequal survivorship: A multi-outcome analysis of LGBTQ+ disparities among adolescent and young adult cancer survivors in the VOICE study.**
First Author: Austin R. Waters, PhD, MSPH
- Board G13 Abstract 360: Adoption of an interdisciplinary women's wellness and menopausal symptom management clinic.**
First Author: Melissa Matson, ANP-BC, AOCNP
- Board G14 Abstract 361: Food insecurity documentation among cancer survivors referred to a food assistance program.**
First Author: Jessica Suebin Yoon, BS
- Board G15 Abstract 362: Multifaceted aspects of living with long-term metastatic breast cancer.**
First Author: Ashley Pariser Davenport, MD
- Board G16 Abstract 363: Health insurance and unmet food, housing, and transportation needs among cancer survivors: Implications for survivorship care.**
First Author: Anne C. Kirchhoff, PhD
- Board G17 Abstract 364: The association between information-seeking for health-related social needs and subsequent emergency department utilization among patients with cancer.**
First Author: Julia Stal, PhD
- Board G18 Abstract 365: Photobiomodulation (PBM) for radiodermatitis in patients with head and neck cancer (HNC) undergoing radiotherapy: A large real-world cohort and benchmarking against historical data.**
First Author: Renata Ferrari, BS
- Board G19 Abstract 366: Healthcare utilization associated with immune-related adverse events in gastrointestinal malignancies: A systematic review and meta-analysis.**
First Author: Rithika Manjunatha Reddy, MD
- Board G20 Abstract 367: Opportunities to advance head and neck cancer survivorship care: Perspectives from community oncology providers (HN-STAR WF-1805CD).**
First Author: Sarah Asad, PhD, MSc
- Board G21 Abstract 368: Route- and formulation-specific safety profiles of short-acting opioids for breakthrough cancer pain: A systematic review and meta-analysis.**
First Author: John Sungmin Koh, MD
- Board G22 Abstract 369: Comparative reporting of serious neurologic toxicity and hospitalization with tarlatamab vs standard subsequent-line therapies for extensive-stage small cell lung cancer: A FAERS analysis.**
First Author: Roshini Pasala
- Board G23 Abstract 370: Promoting gynecologic cancer patients to achieve functional recovery (PROOF) cohort study: Interim analysis of longitudinal outcomes.**
First Author: Stephanie Cham, MD, MS
- Board G24 Abstract 371: Comparison of the toxicity assessment clinic and the emergency department for oncology patients receiving systemic therapy.**
First Author: Andrew R. Maher, BSc
- Board H1 Abstract 372: Chronomodulated versus conventional chemotherapy scheduling in colorectal cancer: A systematic review and meta-analysis of toxicity and treatment outcomes.**
First Author: Tapeshe Lalotra
- Board H2 Abstract 373: Changes in cognition of older adults with myeloid neoplasms in a pilot randomized controlled trial of a mobile health exercise intervention.**
First Author: Jonas M. Ndeke, MD, PhD, MPH
- Board H5 Abstract 376: Multisystem toxicity signals of antibody–drug conjugates in solid tumors: A FAERS pharmacovigilance analysis, 2020–2025.**
First Author: Zouina Sarfraz, MBBS
- Board H6 Abstract 377: Impact of a leukotriene receptor antagonist premedication strategy on chair time, rescue medication use, and drug waste associated with rituximab infusions.**
First Author: Sian Anwyn Behrendt-McLeroy, BS, MS, PharmD
- Board H7 Abstract 476: Reducing prior authorization burden in oncology: A systematic review of interventions and outcomes.**
First Author: Anchu Ann Vincent, MD
- Board H8 Abstract 477: Systematizing quality improvement: Aligning barriers and interventions to boost adult oncology vaccination rates.**
First Author: Janette Merrill, DH
- Board H9 Abstract 478: Implementation of a medical unmet needs framework in multiple myeloma using Humana Medicare Advantage prescription drug plan claims data.**
First Author: Alexjandro Daviano
- Board H10 Abstract 479: Time to treatment in lung cancer: Insights from a pilot lung cancer patient navigation program in a safety-net county hospital.**
First Author: Mrinal Ranjan, MPH
- Board H11 Abstract 480: Multisite quality improvement workshops to improve adverse event monitoring and supportive care delivery in HR+, HER2–metastatic breast cancer.**
First Author: Teresa van Oort, MHA, MSW
- Board H12 Abstract 481: Integrating education into a statewide quality initiative to improve biomarker testing in metastatic NSCLC.**
First Author: Allison Schepers, BCOP, PharmD

Board H13	Abstract 482: Comparative analysis of radiation oncology treatment efficiency by anatomical site. First Author: Ajay Dubey, MD, MPH	Board J3	Abstract 496: Co-designing a patient communication aid for timely postoperative radiotherapy in head and neck cancer. First Author: Hannah Crowe-Cumella, MSW
Board H14	Abstract 483: Influence of patient-reported symptom monitoring on adherence to oral targeted therapy: A multicenter complex intervention study. First Author: Ana Maria Teixeira Pires, PhD	Board J4	Abstract 497: Hub and spoke models in oncology: A scoping review. First Author: Hailey Leiva, MSW
Board H15	Abstract 484: From standard to system: Implementing integrated tobacco cessation and lung cancer screening across a multi-site oncology network. First Author: Joshua Rusheen, MD	Board J5	Abstract 498: Implementation of scalable ePRO monitoring in oncology care delivery: Operational impact and workforce redesign. First Author: Angela Geistkemper, BSN
Board H16	Abstract 485: Centralized electronic prior authorization for inpatient oral antineoplastics: A pilot quality improvement initiative. First Author: Aaron D. Goldberg, MD, PhD	Board J6	Abstract 499: Operationalizing learning health system principles through PROMs implementation: A stakeholder-engaged decision-making process in cancer care. First Author: Farah Elsis, MS
Board H17	Abstract 486: Improving documentation of complete cancer family history in an oncology quality improvement collaborative. First Author: Emerson Delacroix, MA	Board J7	Abstract 500: Evaluating a reflex next-generation sequencing as a quality improvement strategy in advanced NSCLC: Early experience from a large southern U.S. health care system. First Author: Marc Ryan Matrana, MD, MS, FACP
Board H18	Abstract 487: Beyond national benchmarks: An EMR-integrated platform for measuring local time to treatment infusion. First Author: Tulsi Patel, MD, MPH	Board J8	Abstract 501: Use of a comprehensive, mobile application to assist cancer patients with diet, nutrition, and activity: A feasibility study of the Restore-Me app. First Author: Adriana Carrieri, PhD
Board H19	Abstract 488: Immune checkpoint inhibitor–related endocrinopathies: Real-world assessment strategies and best practices. First Author: Hala Awad, PhD, MS, MSc, PharmD	Board J9	Abstract 502: Implementing a leadership collaborative to build organizational capacity for data-driven improvement and operational excellence in community oncology. First Author: Olivia Jennifer Barrett, RN, MBA, OCN
Board H20	Abstract 489: Implementing PI3K/PTEN testing using IHI PDSA cycles. First Author: Vivek Kumar, MD, MBBS	Board J10	Abstract 503: From directive to practice: Operationalizing a system-level systemic anticancer therapy (SACT) oversight program at a large academic cancer center. First Author: Narmeen Somani
Board H21	Abstract 490: Improving infusion center efficiency and reducing wait times using a data-driven scheduling platform. First Author: Esther Harrison, RN	Board J11	Abstract 504: Adjuvant CDK 4/6 inhibitor utilization in breast cancer in a large community practice. First Author: Kathryn Elizabeth Hudson, MD
Board H22	Abstract 491: Bridging the quality improvement gap in conflict-affected healthcare: A structured training program for Syria. First Author: Omer Abdrabbuh, MD	Board J12	Abstract 505: Impact of community health workers on breast cancer care and clinical trial enrollment intent: A pilot study. First Author: Yehoda M. Martei, MD, MSCE
Board H23	Abstract 492: Implementation of a systemwide electronic order set to standardize the initial management of suspected acute leukemia. First Author: Dawood Hasan Syed, MD	Board J13	Abstract 506: Improving the use of bone modifying agents for patients with prostate cancer. First Author: Aaron Philip Mitchell, MD, MPH
Board H24	Abstract 493: Increasing advance care planning documentation via an electronic medical record (EHR) pre-visit intervention for patients initiating new palliative intent systemic treatments. First Author: Grace Sharifi	Board J14	Abstract 507: Implementation of a phased hepatitis B virus screening and management program for patients receiving systemic anticancer therapy. First Author: Tanvi Dandawate
Board J1	Abstract 494: Pilot phase II trial of quick start durvalumab after chemoradiation for unresectable stage II-III non-small cell lung cancer. First Author: Thomas William Lycan Jr., MHS, DO	Board J15	Abstract 508: Real-world implementation of an AI-guided care pathway to accelerate NSCLC biomarker testing in a community health system. First Author: Yunus Emre Demirhan, MD
Board J2	Abstract 495: Integrating patient-reported outcomes into routine oncology practice: A hybrid type 3 implementation study of FRAME-PRO-CR. First Author: Johanne Dam Lyhne, MD		

Board J16	Abstract 509: Health-related social needs screening in community oncology settings: Results from a national sample of NCORP clinics (WF-2303CD). First Author: Emily Ruth Haines, PhD	Board K6	Abstract 522: Complications following implantable venous access port placement: Surgery versus interventional radiology. First Author: Ria Nuna, BS
Board J17	Abstract 510: Process mapping of ePRO-enabled remote symptom monitoring across academic and community practices. First Author: Nicole Lynn Henderson, PhD, MPH	Board K7	Abstract 523: Know when to hold 'em: A QI initiative to reduce bleeding events in patients on BTK inhibitors. First Author: Meredith Gallagher, MD
Board J18	Abstract 511: Evaluating the feasibility and scalability of a volunteer oncology navigation support model: American Cancer Society Community Access to Resources, Education and Support (ACS CARES). First Author: Charlotte Waugh, BS	Board K8	Abstract 524: Antibody-drug conjugate-associated pneumonitis (AAP) across novel first-in-human phase I trials: A pooled single-center analysis. First Author: Falah Fayaz, MD
Board J19	Abstract 512: Developing a clinical pathway that integrates point-of-care at-home testing for patients with suspected febrile neutropenia: A UK Delphi consensus study. First Author: Saif Ahmad, MD, PhD	Board K9	Abstract 525: The oncology capability gap: Failure-to-rescue following high-risk oncologic emergencies in the United States. First Author: Daniel Thomas Jones, DO, MHS, MBA, BS
Board J20	Abstract 513: Champion experience and implementation success in a multi-center care delivery improvement collaborative. First Author: Kristen McNiff Landrum, MPH, DPH	Board K10	Abstract 526: The longitudinal trajectory of immunotherapy-related toxicities: Assessing national trends in inpatient mortality and financial resource utilization across U.S. health systems (2017–2023). First Author: Vahin Vittal Gaduputi
Board J21	Abstract 514: Access to T-cell engaging bispecific antibody therapy through a decentralized community oncology model. First Author: Samip R. Master, MD, MBBS	Board K11	Abstract 527: Assessing preventable harm in U.S. cancer care: National trends in preventable oncology hospitalizations, 2017–2023. First Author: Vahin Vittal Gaduputi
Board J22	Abstract 515: Vaccination timing, uptake, and risk factors for under-vaccination among patients receiving immune checkpoint inhibitors: A real-world cohort analysis. First Author: Emily Kolyvas, MD, PhD	Board K12	Abstract 528: Adoption and practice variation of <i>DPYD</i> genotyping prior to fluoropyrimidine therapy at two Canadian cancer centres. First Author: Sara Ladak
Board J23	Abstract 516: From evidence to action: Peer transparency and implementation readiness in HER2-low/ultralow breast cancer. First Author: Caroline Pardo, PhD	Board K13	Abstract 529: Counterfeit and substandard medicine awareness among oncology clinicians at a US academic medical center: A qualitative study. First Author: Jean Christophe Rusatira, MD, PhD, MPH
Board K1	Abstract 517: ASCO Patient-Centered Cancer Care Standards in virtual care: Evolution and implementation in a national virtual oncology clinic. First Author: Rebecca A. Miksad, MD, MPH, MMedSc	Board K14	Abstract 530: Risk factors for fatal dermatologic toxicity associated with enfortumab vedotin: A multicenter retrospective review. First Author: Alaa Muslimani, MD
Board K2	Abstract 518: Real-world uptake and care delivery variation in somatic and germline HRR testing for metastatic prostate cancer. First Author: Anish Kumar Shah, MD, MBBS	Board K15	Abstract 531: Safety, tolerability, and pharmacokinetics (PK) of luspatercept (LUSPA) at increased injection volumes (up to 2 mL) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) who require red blood cell (RBC) transfusions: Results from MAXILUS. First Author: Ali McBride, MS, PharmD
Board K3	Abstract 519: Implementation of a pharmacy hard stop for pre-treatment <i>DPYD</i> genotyping before fluoropyrimidine therapy: A single-center quality improvement study. First Author: Kevin C. Wood, MD	Board K16	Abstract 532: Safety outcomes of off-unit inpatient chemotherapy and biologics administration through Chemo Without Borders, a structured certified-nurse deployment program. First Author: Tulsi Patel, MD, MPH
Board K4	Abstract 520: Implementing a standardized PIVC training for nurses in an outpatient infusion unit: A quality improvement project. First Author: Sarah Woods Paiva, DNP, FNP, RN	Board K17	Abstract 533: Should oncology teams reassess GLP-1 receptor agonist management during cancer care? A meta-analysis. First Author: Zouina Sarfraz, MBBS
Board K5	Abstract 521: Implementation of a novel, multifaceted program to improve MD and APP-identified safety event reporting. First Author: Daniel Aaron Roberts, MD		

Board K18	Abstract 534: DPYD testing patterns following FDA black box warning in large community oncology practice. First Author: Brian Grieb, MD, PhD	Board L7	Abstract 547: Integrating clinical and social determinants to predict breast cancer stage at diagnosis. First Author: Semimo Adeleke, MBBS, MPH
Board K19	Abstract 535: Weekend admission effect on inpatient mortality among cancer patients: A National Inpatient Sample analysis, 2017–2023. First Author: Anuv Shevde	Board L8	Abstract 548: Implementation of a biomarker-preserving bone biopsy decalcification workflow for oncology patients: A single-center quality improvement initiative. First Author: Vasu Malhotra, DO
Board K20	Abstract 536: National trends in dihydropyrimidine deficiency testing before fluoropyrimidine chemotherapy. First Author: Arthur S. Hong, MD, MPH	Board L9	Abstract 549: Association of protein-energy malnutrition with inpatient outcomes and resource utilization in pancreatic cancer. First Author: Alexandra Sueldo, MD
Board K21	Abstract 537: Prospective optimization of potentially inappropriate medications in older adults with cancer guided by an NCCN-adapted scale (GO-PIMs). First Author: Mayuri Dharne, MS, MPH	Board L10	Abstract 550: Adherence and postoperative outcomes following implementation of an enhanced recovery protocol for pancreaticoduodenectomy. First Author: Manav Shah, MD
Board K22	Abstract 538: Examining patient-reported falls and frailty to identify fall risk in older adults with GI cancer at an ambulatory oncology center. First Author: Michael Manni, MHA	Board L11	Abstract 551: Delays in oncologic care for newly diagnosed thoracic malignancies: A quality improvement analysis at a single institution. First Author: Aariez Khalid
Board K23	Abstract 539: Predictors of frequent (≥3) unplanned hospitalizations after chemotherapy in solid tumor patients. First Author: James Liu, MD	Board L12	Abstract 552: Cancer patients' comfort with artificial intelligence in oncology care and first-round "AI chemo-teach" quality improvement initiatives. First Author: Sunil Dommaraju, MD, BS
Board K24	Abstract 540: Somatic-to-germline concordance rates in clinically actionable cancer predisposition genes. First Author: Abigail Macher	Board L13	Abstract 553: Occupational health and psychosocial well-being in African women with breast cancer: A systematic review. First Author: Jean Paul Muambangu Milambo
Board L1	Abstract 541: Implementing an oncology command center model during a large-scale labor disruption. First Author: Nina Hart, MHA	Board L14	Abstract 554: Bridge the gap: Improving outcomes and satisfaction in ASCC survivor transitions using QI. First Author: Jackie Edwards
Board L2	Abstract 542: Leveraging electronic psychosocial distress screening to identify food insecurity and deliver targeted interventions in oncology care. First Author: Shreya Modi, MHA	Board L15	Abstract 555: Short-acting G-CSF use beyond chemotherapy-associated neutropenia: A quality improvement review in solid organ transplant recipients. First Author: Nitya Batra, MBBS
Board L3	Abstract 543: Distress trajectories as indicators of biopsychosocial supportive care vulnerability in a nationwide PRO-based oncology program. First Author: Cristiane Decat Bergerot, PhD, MS, FASCO	Board L16	Abstract 556: Real-world pathologic complete response after neoadjuvant chemotherapy in a safety-net breast cancer population. First Author: Nancy Nguyen, DO
Board L4	Abstract 544: Transitioning from reactive to pretreatment DPYD testing through a system-wide screening program at a comprehensive cancer center. First Author: Victoria Higbie, MD	Board L17	Abstract 557: Improving tobacco use screening and smoking cessation referrals through electronic health record workflow redesign and nursing education in oncology clinics. First Author: Matthew Lu, MD, BS
Board L5	Abstract 545: Addressing cancer prevention needs through a comprehensive, risk-stratified cancer prevention program. First Author: Michelle Zimmerman, JD, MBA	Board L18	Abstract 558: Improving access and timeliness of oncology treatment education through a standardized video-based model. First Author: Melissa Shaw, BSN
Board L6	Abstract 546: Use of the Electronic Frailty Index (eFI) to identify older adults with increased healthcare needs after receiving CAR-T therapy. First Author: Mark R. Korst, MD	Board L19	Abstract 559: Implementing a standardized anticoagulation protocol to reduce catheter-related thrombosis (CRT) on an inpatient lymphoma service. First Author: Yiran Emily Peng, MD, MBA

- Board L20 Abstract 560: Evaluating clinical indications for hospital-at-home for patients with cancer: A modified Delphi consensus approach.**
First Author: Sahil D. Doshi, MD
- Board L21 Abstract 561: Non-medical needs in oncology patients: Patient-reported outcomes collected in a statewide consortium.**
First Author: Shayna Weiner, MPH
- Board L22 Abstract 562: Connected in purpose, united in care.**
First Author: Amy Gallagher, PsyD
- Board L23 Abstract 563: Malnutrition in haematological malignancies: A nationwide analysis of outcomes, resource utilisation, and disparities (NIS 2021-2022).**
First Author: Jude O. Ossai, MD
- Board L24 Abstract 564: Leveraging quality improvement principles to reduce steroid-induced hyperglycemia rates on an inpatient lymphoma service.**
First Author: Jayme Kunze, PA-C, MS
- Board M1 Abstract 565: Identifying clinically important indicators for providing high quality breast cancer care.**
First Author: Delon Dick Lon Chan, MD
- Board M2 Abstract 566: Quality of care in US community oncology practices among patients with metastatic breast cancer (mBC) and metastatic non-small cell lung cancer (mNSCLC).**
First Author: Stephen G. Divers, MD
- Board M3 Abstract 567: Oncologist and oncology patient perceptions of RSV vaccination to inform quality improvement interventions.**
First Author: Lisa Y. Law, MD, FASCO
- Board M4 Abstract 568: Improving clinical trial prescreening accuracy for older adults with metastatic breast cancer: An ASCO quality training program initiative.**
First Author: Emily Meichun Ko, MD
- Board M5 Abstract 569: Quality improvement initiative to enhance tobacco screening and referral rates through electronic medical record changes and virtual care integration.**
First Author: Sun Choi, BSc
- Board M6 Abstract 570: AI-driven pathology report classification to expedite oncology care coordination: A quality improvement study in endometrial cancer.**
First Author: Jack Martinyan, MD
- Board M7 Abstract 571: The individualized treatment plan: A model for standardizing patient-centered cancer care—The experience of Medisprof Cancer Center.**
First Author: Raluca Stupar
- Board M8 Abstract 572: The utility of routine preoperative MRI in the management of newly diagnosed breast cancer in a safety net population.**
First Author: Ananya Murthy, BS
- Board M9 Abstract 573: Impact of a novel advanced support unit on intensive care unit mortality at a comprehensive cancer center.**
First Author: Joshua Botdorf, DO, FACP
- Board M10 Abstract 574: Addressing gaps in pre-screening for interventional clinical trials among patients with newly diagnosed lung cancer, lymphoma, and multiple myeloma.**
First Author: Jessica Amalraj, MD, MA
- Board M11 Abstract 575: Symptom burden and interventions in veterans enrolled in the Proactive Response for Individual Symptom Management (PRISM) program.**
First Author: Denaly Chen, MD
- Board M12 Abstract 576: Implementation of an iron deficiency anemia screening and treatment program in a gynecologic oncology department at a comprehensive cancer center.**
First Author: Gavin Ovsak, MD
- Board M13 Abstract 577: Transitioning to in-house methotrexate level testing for patients receiving high-dose methotrexate.**
First Author: Jeremy Schmoyer, DO
- Board M14 Abstract 578: ASCO QTP project to improve equity in cancer clinical trials.**
First Author: Monica Arun Patel, MD
- Board M15 Abstract 579: Driving efficiency in oncology care: Tactical solutions for inpatient flow challenges.**
First Author: Catherine Delanoix, BSN
- Board M16 Abstract 580: Improving germline genetic testing and genetic counseling referral in prostate, pancreatic, and colorectal cancer through a multidisciplinary quality improvement intervention.**
First Author: Yusra B. Medik, MD
- Board M17 Abstract 581: Delayed biliary drainage and inpatient outcomes in pancreatobiliary malignancy: A National Inpatient Sample analysis, 2020-2023.**
First Author: Tong Ren, MD, PhD
- Board M18 Abstract 582: Results from a multisite quality improvement initiative in solid tumor precision medicine.**
First Author: Amany R. Keruakous, MD, MS
- Board M19 Abstract 583: Impact of a short questionnaire on identification and referral for hereditary cancer syndromes in a resident-run clinic.**
First Author: Murtaza Qazi, MD
- Board M20 Abstract 584: Closing the HRR testing gap in advanced prostate cancer: Influence of audit-feedback on testing and sustainability.**
First Author: David Michael Waterhouse, MD, MPH, FASCO
- Board M21 Abstract 585: Perceived barriers and facilitators to improving lung cancer screening among primary care providers in an academic teaching hospital: A qualitative needs assessment.**
First Author: Asha Elina Kodan, MD

Board M22	Abstract 586: Impact of standardized rate titration on infusion-related reactions to paclitaxel chemotherapy. First Author: Sara Moore, MD	Board N13	Abstract 600: Optimization of the outpatient infusion center workflow for subcutaneous targeted therapy and immunotherapy in cancer patients. First Author: Isabel Tuñón Cabeza, BSN, NP
Board M23	Abstract 587: Sex, racial, and regional disparities in dementia-associated mortality among adults with hematologic malignancies in the United States, 1999–2024. First Author: Navnita Kumari, MBBS	Board N14	Abstract 601: Quilting sutures vs conventional closure after breast cancer mastectomy: A meta-analysis of seroma prevention and its oncologic implications. First Author: Shreya Khankar, MBBS
Board N1	Abstract 588: Impact of multi-modal quality improvement on colorectal cancer screening among people experiencing homelessness at a safety-net clinic. First Author: Sunil Dommaraju, MD, BS	Board N15	Abstract 602: 10 years of QOPI certification in Spain: Driving continuous quality improvement in oncology practice. First Author: Jesus Garcia-Foncillas, MD, PhD
Board N2	Abstract 589: Mortality trends and demographic patterns in malignant neoplasms of independent primary multiple sites in United States, 1999-2023: Analysis of national data from CDC WONDER database. First Author: Palwasha Asghar	Board N16	Abstract 603: Outcomes of inpatient chemotherapy following multidisciplinary review in patients with solid tumors at an academic cancer center. First Author: Lawanya Singh, MD
Board N3	Abstract 590: Rectal cancer radiotherapy quality improvement: Implementation in an LMIC setting. First Author: Shubham Khanolkar, MBBS	Board N17	Abstract 604: Improving clinical trial prescreening documentation in safety-net oncology teaching clinics using an EHR SmartPhrase with embedded trial availability. First Author: Joseph Vento, MD, MS
Board N4	Abstract 591: A quality improvement initiative to optimize somatic and germline testing in prostate cancer. First Author: Arjun Pon Avudaiappan, MCh	Board N18	Abstract 605: Improving healthcare proxy documentation among hospitalized solid tumor patients: A quality improvement initiative. First Author: Lawanya Singh, MD
Board N5	Abstract 592: Rationalizing post-infusion observation times for monoclonal antibodies and antibody-drug conjugates used for the treatment of solid tumors. First Author: Sara Moore, MD	Board N19	Abstract 606: Universal social needs screening with reflexive social work notification among new patients with pancreatic cancer. First Author: Kever Anthony Lewis, MD, MS
Board N6	Abstract 593: Reducing genomic testing turnaround time through a multidisciplinary quality improvement initiative at a safety-net hospital. First Author: Anthony Jacob Ursua, DO	Board N20	Abstract 607: A culture change initiative to reduce end-of-life systemic anticancer therapy and intensive healthcare utilization. First Author: Ravin Ratan, MD
Board N7	Abstract 594: Optimal carboplatin dosing strategy for the KEYNOTE-522 regimen: A retrospective analysis. First Author: Emily Hansinger, MD	Board N21	Abstract 608: Leveraging patient-reported and health record data to monitor oncofertility care among adults with cancer: A proof-of-concept study. First Author: Nadine A. Jackson, MD, MPH, BSN
Board N8	Abstract 595: Characterizing after-hours oncology triage calls to improve patient safety and resource utilization. First Author: Matthew Guo, MD	Board N22	Abstract 609: Hospital readmissions in breast medical oncology patients: A retrospective analysis. First Author: Elysa Monique Cortez, MD
Board N9	Abstract 596: Clinical drivers and early outcomes of inpatient chemotherapy in gastrointestinal oncology: A retrospective cohort study. First Author: Anas Barabrah	Board N23	Abstract 610: Improving clinical trial enrollment rates among patients with operable invasive breast cancers: An ASCO Quality Training Program initiative. First Author: Mike Zhou Yang, MD, BS
Board N10	Abstract 597: Does timing of psychiatry consultation matter in hospitalized head neck surgical oncology patients? A pre-post quality initiative at a comprehensive cancer center. First Author: Deepti Chopra, MBBS	Board N24	Abstract 611: Improving colorectal cancer screening in an underserved population through resident-led outreach and EHR reconciliation. First Author: Shivangi Sharma, MBBS
Board N11	Abstract 598: Improving sepsis care in patients undergoing stem cell transplant and cellular therapy. First Author: Gazal Gulati, MD	Board P1	Abstract 612: Systemic anticancer therapy near the end of life and acute health care utilization: A target trial emulation study using SEER–Medicare. First Author: Maureen Canavan, PhD, MPH

Board P2	Abstract 613: Improving malnutrition screening and timely nutrition assessment for hospitalized patients with cancer: A quality-improvement initiative. First Author: Maksim Isachanka, MD	Board P15	Abstract 626: Leveraging automation to accelerate prescreening in genitourinary oncology clinical trials at an academic cancer center. First Author: Hiba M. Khan, MD, MPH
Board P3	Abstract 614: Guideline-recommended calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: Documentation patterns and bone outcomes in a real-world cohort. First Author: Aya Abdoh, MD	Board P16	Abstract 627: Underutilization of bone-modifying agents in multiple myeloma: A national real-world quality gap analysis. First Author: Ayesha Laraib-Ijaz, MBBS
Board P4	Abstract 615: Advancing equitable cancer care for LGBTQ+ patients through education, action planning, and inclusive practice change. First Author: Kelly E. McKinnon, PhD	Board Q1	Abstract 628: Implementation of <i>DPYD</i> genetic testing at a safety net oncology clinic. First Author: Constance Fiocco, MD
Board P5	Abstract 616: Oncology patients, cancer type, and rapid response service use: A retrospective cohort study in a large integrated health system. First Author: Chuanfen Ni, MSW	Board Q2	Abstract 629: Creating a pause: An EHR intervention supporting goal-concordant care during acute care transitions. First Author: Tony Kin Wai Hung, MD, MS, MBA, FACP
Board P6	Abstract 617: Improving the veteran experience at the VA East Orange chemotherapy infusion clinic. First Author: Ilana Pyatetsky, DO	Board Q3	Abstract 630: Improving timely beta-lactam antibiotic administration for suspected sepsis in an ambulatory oncology practice. First Author: Jessica McGuire, RN, OCN
Board P7	Abstract 618: Beyond the mortality metrics: A multidisciplinary approach to advancing high-value end-of-life care. First Author: Katherine Shoush Cools, MD	Board Q4	Abstract 631: Feasibility study of leveraging generative artificial intelligence to characterize reasons for treatment discontinuation among patients with gastrointestinal cancers. First Author: Chengbo Zeng
Board P8	Abstract 619: The certification gap in rural chemotherapy delivery: A Minnesota All-Payer Claims analysis. First Author: Abigail Paige Swenson, MD	Board Q5	Abstract 632: Manual review of electronic medical record (EMR) versus artificial intelligence (AI) for detection of immune-related adverse events (irAE) in patients (pts) with stage IV non-small cell lung cancer (NSCLC). First Author: Vanessa Fang
Board P9	Abstract 620: Efficacy-toxicity paradox of perioperative immune checkpoint inhibitors: An ESMO-MCBS v2.0 quality analysis of FDA approvals. First Author: Haritha Gandicheruvu, MD	Board Q6	Abstract 635: Advanced practice provider perspectives on survivorship care models, care coordination, and survivorship resources. First Author: Lauren Victoria Ghazal, PhD, APRN-BC
Board P10	Abstract 621: Proactive treatment readiness review to reduce radiation therapy no-fly events. First Author: Jameson Baker	Board Q7	Abstract 636: Advanced practice provider preparedness for cancer survivorship care: A health system-wide survey. First Author: Lauren Victoria Ghazal, PhD, APRN-BC
Board P11	Abstract 622: Impact of structured lung cancer screening program and outreach interventions on screening uptake at an academic health center. First Author: Merin Jose, MBBS	Board Q8	Abstract 637: Implementation of an interdisciplinary breast cancer survivorship clinic: Impact on distress and patient experience in the community setting. First Author: Lauren Cornell, MD
Board P12	Abstract 623: Surrogacy between event-free survival and overall survival in perioperative immunotherapy trials. First Author: Haritha Gandicheruvu, MD	Board Q9	Abstract 638: Receipt of surveillance in a population-based sample of survivors of early-onset colorectal cancer. First Author: Christine M. Veenstra, MD, MS
Board P13	Abstract 624: First things first: A quality improvement initiative to increase enrollment to biobanking studies for clinical trial eligibility of children with newly diagnosed leukemia. First Author: Laura Padilla, PhD	Board Q10	Abstract 639: Comparative effectiveness of CAR-T cell therapy and CD20xCD3 bispecific antibodies in relapsed/refractory follicular lymphoma: A propensity score-matched real-world analysis. First Author: Navya Pillikunte Doddareddy, MD
Board P14	Abstract 625: Preparing frontline physicians for cancer immunotherapy toxicities: A quality improvement initiative. First Author: Vasu Bansal, MBBS	Board Q11	Abstract 640: Impact of extranodal disease burden on survival following CAR-T therapy in relapsed/refractory large B-cell lymphoma: A propensity score-matched multi-center analysis. First Author: Navya Pillikunte Doddareddy, MD

Board Q12	Abstract 641: Developing provincial cancer survivorship standards to inform quality of care in Ontario, Canada. First Author: Muna Al-Khaifi, MD, MPH	Board R12	Abstract 654: The association between offspring age at parental cancer diagnosis and later adult lifestyle behaviors: Findings from the Cancer Prevention Study-3. First Author: Ruiqi Jin, PhD
Board Q13	Abstract 642: Digital remote monitoring to improve adherence, safety, and healthcare utilization in oral anticancer therapy: A systematic review. First Author: Mahboob Younus Shaik, MD	Board R13	Abstract 655: Neurofilament light as a biomarker for chemotherapy-induced peripheral neuropathy in patients receiving taxane-based chemotherapy. First Author: Tallat Mahmood, MD
Board R1	Abstract 643: Burden of adverse lifestyle risk among cancer survivors with pregnancy: A comparative analysis using 2011-2024 BRFSS data. First Author: Neeraj Bhandari	Board R14	Abstract 656: Aligning survivorship care with patient priorities for older adult breast cancer survivors. First Author: Geethika Yalavarthy
Board R2	Abstract 644: Cancer survivorship and guideline-concordant screening: Assessment of gaps in colorectal, breast, and cervical cancer screening despite increased healthcare contact (BRFSS 2024). First Author: Maria Felix Torres Nolasco, MD	Board R15	Abstract 657: Is it time to revisit the role of survivorship care plans? First Author: Anne Hudson Blaes, MD, MSc
Board R3	Abstract 645: Food insecurity and uncontrolled cancer-related pain among adult cancer survivors: A 2022 BRFSS analysis. First Author: Fatemeh Alibeiki, MD	Board R16	Abstract 658: Symptom burden and unmet supportive care needs in a population-based sample of early-onset colorectal cancer survivors. First Author: Lauren P. Wallner, PhD, MPH
Board R4	Abstract 646: Cancer surveillance in survivors of adolescent and young adult (AYA)-onset breast and colon cancers from the VOICE study. First Author: Erin Elizabeth Hahn, PhD, MPH	Board S1	Abstract 659: Hypertension-attributable mortality among older adult cancer survivors. First Author: Victoria Marie Telles, BA, MPH
Board R5	Abstract 647: Evaluating breast cancer screening concordance in survivorship care. First Author: Whitney Thoman	Board S2	Abstract 660: Real-world comparative evaluation of long-term outcomes among patients with ovarian cancer receiving olaparib versus niraparib: A global federated health research network analysis. First Author: Yajur Arya, MD
Board R6	Abstract 648: Value-based care models adapted for breast cancer in Morocco: Cost-effectiveness of task-shared multidisciplinary pathways in LMIC settings. First Author: Mouna Azaroual	Board S3	Abstract 661: Quality of life and financial toxicity among survivors of small cell lung cancer. First Author: Jeffrey Yinhong Zhong, MD
Board R7	Abstract 649: Association of semaglutide or tirzepatide and tobacco use disorder in patients with cancer history and type 2 diabetes: A real-world cohort study. First Author: Chuan Angel Lu, MD, MPH	Board S4	Abstract 662: Evaluation of a text message-based approach to depression screening among cancer survivors: The OASIS pilot RCT. First Author: Evan Michael Graboyes, MD, MPH, FACS
Board R8	Abstract 650: Retrospective analysis of high dose capsaicin 8% patches for chemotherapy-induced peripheral neuropathy. First Author: Cristina Fowler, MN	Board S5	Abstract 663: Stories of survivorship: A narrative analysis of the queer/trans cancer StoryListening intervention. First Author: Elise Tarbi, PhD, APRN-BC, RN, NP
Board R9	Abstract 651: Global epidemiologic transition in age-stratified liver cancer mortality etiologies from 1990–2023: A Global Burden of Disease analysis. First Author: Shree Rath, MBBS	Board S6	Abstract 664: Genetic testing–related recall, psychosocial impact, and decision regret among patients with breast cancer in a mainstream genetic testing model. First Author: Taylor Urban, MS
Board R10	Abstract 652: Comparing frailty and health outcomes in AYA cancer survivors to propensity-matched non-cancer controls: A secondary analysis of NHANES data. First Author: Abigail Lustyik, BSN, RN	Board S7	Abstract 665: Baseline association between financial burden and mental health symptoms among cancer survivors enrolled in a health insurance navigation program: A report from the Childhood Cancer Survivor Study. First Author: Zoe Troubh, BA
Board R11	Abstract 653: ASCVD risk assessment in cancer survivorship care. First Author: Whitney Thoman	Board S8	Abstract 666: Exploring how young adult survivors of childhood and adolescent cancer cope with late effects. First Author: Nathan Cao, BA

Board S14 Abstract 667: Changing patterns in mental health visit utilization and spending among US cancer survivors post-COVID.

First Author: Fiza Alam, BS

Board S15 Abstract 668: Adherence to guideline-recommended low-dose CT lung cancer screening among breast cancer survivors with a history of tobacco use.

First Author: Rachel Fan

Board S16 Abstract 669: Evaluation of characteristics and outcomes of head and neck squamous cell carcinoma in post-transplant patients.

First Author: Lendy Chu, MD, MPH

7:20 AM-8:20 AM and 11:40 AM-1:00 PM

Poster Session B

Level 2, Hall D

Posters by Topic

Health Care Access

- Access to and Utilization of Palliative and Supportive Care: A1-A13
- Access to Clinical Trials: A14-A24, B1-B24, C1-C3
- Access to Timely Detection and Referral: C4-C23, D1-D9
- Access to Treatment: D10-D24, E1-E22
- Discrepancies in Care: E23, E24, F1-F23, G1-G22
- Interventions and Policies to Optimize Health Outcomes: G23, G24, H1-H8, H10-H24, J1, J2

Patient Experience

- Communication and Shared Decision-Making Research: J3-J23, K1, K2
- Coordination and Continuity of Care: K3-K13
- Integrating Patient Experience Assessment and Patient Reported Outcomes Into Practice: K14-K24, L1-L23
- Patient and Advocate Engagement: L24, M1-M3
- Provider Impact on Quality From the Patient Perspective: M4, M5
- Symptom Prevention, Assessment, and Management: M6-M23, N1

Technology and Innovation in Quality of Care

- Decision Support Tools: N2-N17
- Impact of Telemedicine: N18-N23
- Real-World Evidence: N24, P1-P16, Q1-Q3
- Tools for Care Coordination: Q4-Q10
- Tools for Management of Treatment and Adverse Effects: Q11-Q13, R1-R7
- Tools to Reduce or Eliminate Regulatory and Administrative Burden: R8-R16
- Use of Clinical Pathways: S1-S3
- Use of IT/Analytics to Improve Quality: S4-S16, T1-T3
- Wearable Devices: T4-T6

Board A1 Abstract 84: Pharmacist-led telemedicine follow-up to preserve specialty palliative care access during a staffing shortage at a regional cancer center.
First Author: Caroline Cubbison

Board A2 Abstract 85: Machine learning typology of longitudinal specialty palliative care use among patients with non-small cell lung cancer.
First Author: Haofan Yang, BS, MPH

Board A3 Abstract 86: 20 years of cancer care in people living with HIV: Are we making progress?
First Author: Kim Abbegail Tan Aldecoa, MD

Board A4 Abstract 87: Clinician type at first palliative care encounter among decedents with poor-prognosis advanced cancer: A descriptive analysis using Medicare claims linked to the National Palliative Care Registry.
First Author: John Shin, MPH

Board A5 Abstract 88: Advanced palliative radiation therapy modalities for bone metastases in Medicare advantage versus traditional Medicare.
First Author: Mokshad Gaonkar, MS

Board A6 Abstract 89: Hospital-level patterns of palliative care delivery among patients with advanced cancer: A clustering analysis.
First Author: John Shin, MPH

Board A7 Abstract 90: Use of palliative care consultation in terminal gastrointestinal cancer hospitalizations.
First Author: Azza Sarfraz, MBBS

Board A8 Abstract 91: Using claims-based network measures to identify specialist palliative care providers for patients with advanced cancer.
First Author: Ravi Chandra Thota, PhD

Board A9 Abstract 92: Functional status to predict acute care utilization among patients receiving systemic anticancer therapy in a QMENTUM diamond cancer center: A real-world cohort study.
First Author: Victória Santos Marques Pereira, MD

Board A10 Abstract 93: Who, what, when: A national survey of survivorship care delivery at US cancer centers.
First Author: Ameish Govindarajan, MD

Board A11 Abstract 94: Identifying palliative care providers for patients with advanced cancer: A machine learning approach.
First Author: Ravi Chandra Thota, PhD

Board A12 Abstract 95: Patterns of oncology navigation center contact before acute care utilization among patients receiving chemotherapy.
First Author: McKenna Perrin, MPH

Board A13 Abstract 96: Association of CDC opioid prescribing guidelines with opioid dispensing among patients with head and neck cancer: An interrupted time series analysis.
First Author: Parasto Mousavi, PharmD

Board A14 Abstract 97: Barriers and motivators to clinical trial (CT) participation across metastatic breast cancer (BC), non-small cell lung cancer (NSCLC), and endometrial cancer (EC): Insights to advance equitable access.
First Author: Eric Kumar Singhi, MD

Board A15 Abstract 98: Routine, not random: Implementation of a novel tool for universal clinical trial prescreening.
First Author: Shail Maingi, MD, FASCO

Board A16 Abstract 99: National reach and real-world utilization of myTRIAList: A digital cancer clinical trial platform.
First Author: Alexandra Katherine Zaleta, PhD

Board A17 Abstract 100: Pennsylvania cancer clinical trials Project ECHO: A collaborative strategy to improve clinical trial access in rural and underserved communities.
First Author: Hyma Vani Polimera, MD

Board A18 Abstract 101: Health literacy, language concordance, and perceptions of clinical trials as modifiable barriers to oncology clinical trial participation.
First Author: Alice J. Tao, MD

Board A19 Abstract 102: Operationalizing decentralized clinical trials (DCTs) in community oncology: A thematic analysis of expert roundtable discussions.
First Author: Carolyn Trachtenbrot

Board A20	Abstract 103: Impact of a cancer clinical trial communication workshop on oncology fellows' observed communication skills. First Author: Naomi D. Parker, PhD	Board B10	Abstract 117: Multidimensional barriers and facilitators to early phase clinical trial (EPCT) participation among diverse patients with advanced solid tumors. First Author: Iris Yao, MD
Board A21	Abstract 104: Who is represented? Racial and ethnic demographic reporting in clinical trials cited by NCCN testicular cancer guidelines. First Author: Suhail Sapkota, MD	Board B11	Abstract 118: Patient, caregiver, and clinician perspectives to inform a peer community navigator intervention for early-phase clinical trials participation. First Author: Marina Serrano Fernandez, MD
Board A22	Abstract 105: Understanding the impact of a revised clinical trial protocol template on broadening eligibility. First Author: Ashley Odai-Afotey, MD	Board B12	Abstract 119: Enterprise-wide AI-enabled screening to accelerate clinical trial identification across an integrated cancer network. First Author: Amanda Davis, LPN
Board A23	Abstract 106: MTB-based initiative to match patients with advanced malignancies to clinical trials. First Author: Whitney Rose Swain, BSc	Board B13	Abstract 120: Association of clinical trial participation and transportation and insurance burdens and financial needs among cancer-related crowdfunding campaigns. First Author: Matthew Libre
Board A24	Abstract 107: Screen failure among patients consenting for early phase cancer clinical trials (EPCTs). First Author: Sienna M. Durbin, MD	Board B14	Abstract 121: Recruitment patterns and enrollment barriers in a multisite nonpharmacologic trial for breast cancer survivors with chemotherapy-induced neuropathy. First Author: Melissa Tempest, BSc
Board B1	Abstract 108: Does time from radiographic progression to the start of a clinical trial affect outcomes in metastatic colorectal cancer (mCRC)? First Author: Jarett Feldman, MD	Board B15	Abstract 122: HIV eligibility in federally and industry-led cancer treatment trials before and after the 2017 ASCO–Friends statement. First Author: Hong Xiao, PhD
Board B2	Abstract 109: Clinical trial? Oh, I'm not ready for that! A cross-sectional study evaluating barriers to clinical trial accrual in patients with lung cancer. First Author: Isabel Ruth Preeshagul, DO, MS	Board B16	Abstract 123: Quantifying the impact of protocol design on enrollment and dropout rates in breast cancer clinical trials. First Author: Evon Okidi, ScM
Board B3	Abstract 110: Barriers from referral to enrollment for early phase oncology clinical trials. First Author: Lilin Tong, MD	Board B17	Abstract 124: A retrospective study of biopsy requirements in phase I trials of FDA-approved novel therapeutics. First Author: Christina Boatwright, BS
Board B4	Abstract 111: Miles to medicine: Trial-related travel time and expenses for cancer clinical trial participants. First Author: Sydney Booth, BS, BA	Board B18	Abstract 125: A statewide survey assessing how oncologists navigate the cancer clinical trial landscape. First Author: Jeanette Y. Ziegenfuss
Board B5	Abstract 112: Hospital clinical trial enrollment volume and long-term survival among older adults with cancer. First Author: Allison Lipitz-Snyderman, PhD	Board B19	Abstract 126: Analysis of biomarker testing requirements for lung cancer clinical trial enrollment. First Author: Tod Guidry, PhD
Board B6	Abstract 113: Black women's experiences of recruitment and enrollment in a clinical trial: Relationship building in the social interventions for support during treatment for endometrial cancer and recurrence (SISTER) study. First Author: Leah Franklin	Board B20	Abstract 127: Targeted provider email notifications to support referral to phase 1 breast cancer trials. First Author: Jana Wieland, MD, BS
Board B7	Abstract 114: Impact of remuneration on clinical trial accrual and diversity of trial participants. First Author: Fatima Shaba, MD	Board B21	Abstract 128: Implementing a statewide, multi-institution clinical trial matching platform: Early outcomes from cancertrialconnect.org. First Author: Dylan M. Zylla, MD, MS
Board B8	Abstract 115: Telehealth-based strategies to expand clinical trial participation. First Author: Erin Mary Bange, MD	Board B22	Abstract 129: Characterizing travel burden in oncology clinical trials: A single-institution analysis. First Author: Niharika Duggirala, BS
Board B9	Abstract 116: Non-clinical withdrawal from phase III cancer clinical trials. First Author: Jacob Abrahams, MD		

Board B23	Abstract 130: Who are we missing for clinical trial enrollments and why?: A single center effort to improve clinical trial discussion documentation. First Author: Jessica Dreger McDermott, MD, MS	Board C12	Abstract 143: Implementation and evaluation of a mobile lung cancer screening program through an academic–industry collaboration to improve access in underserved rural and Appalachian Ohio. First Author: Jasleen Pannu
Board B24	Abstract 131: Pilot trial of CTNow, a multilevel clinical trial education and referral coordination intervention to enhance access to cancer clinical trials in rural areas. First Author: Izumi Okado, PhD	Board C13	Abstract 144: Improving breast cancer screening in a rural state: Insights from mobile vs. facility-based mammography. First Author: Mackenzie Wild, MD
Board C1	Abstract 132: Clinical trial enrollment in advanced non-small cell lung cancer (NSCLC): A single-institution analysis of screening, eligibility, and enrollment barriers in a diverse urban cancer center. First Author: Noah Agyepong Osei, MD	Board C14	Abstract 145: Reducing diagnostic delays in uninsured patients: Quality improvement evaluation of an expedited cancer workup clinic in a metropolitan safety-net hospital. First Author: Dominick Zheng, MD
Board C2	Abstract 133: Effect of workflow and opportunity barriers on cancer clinical trial enrollment: A qualitative study of medical oncologists at an major academic and affiliated safety-net practice. First Author: Austin Ivery, BS	Board C15	Abstract 146: Local and state paid-sick leave policies and early-stage diagnosis of colorectal cancer. First Author: Kewei Sylvia Shi, MPH
Board C3	Abstract 134: Geographic patterns of site participation in randomized oncology trials sponsored by U.S.-based organizations. First Author: Joseph M. Unger, PhD	Board C16	Abstract 147: Primary care provider exit and cancer stage at diagnosis among Medicare beneficiaries. First Author: Yousef Chavehpour, PhD
Board C4	Abstract 135: Clinical practice gaps and missed opportunities in early detection of lung cancer (LC): A targeted literature review (TLR) with an implementation science lens. First Author: Leah Fine, MBA	Board C17	Abstract 148: Association of Medicaid expansion and colorectal cancer incidence. First Author: Kewei Sylvia Shi, MPH
Board C5	Abstract 136: The early-onset paradox: Advanced-stage colon cancer at presentation across socioeconomic and health system factors. First Author: Yazmin Reategui-Almonacid, MD, MS	Board C18	Abstract 149: The timing of cervical cancer cytology follow-up for Latinas among a network of community health centers within the United States. First Author: Cirila Estela Vasquez Guzman
Board C6	Abstract 137: Mapping delays and surveillance gaps in lung SBRT within a safety-net health system. First Author: Ansh Purohit, BA	Board C19	Abstract 150: Improving colorectal cancer screening in adults aged 45–49 in resident clinic: A UND-LIVE quality improvement project. First Author: Rita Ahmad, MD
Board C7	Abstract 138: Emergency department involvement in the diagnosis of hematologic malignancies. First Author: Staci Keene	Board C20	Abstract 151: Melanoma incidence and mortality trends following COVID-19–associated disruptions in diagnosis: A population based study. First Author: Milcah Poothakary
Board C8	Abstract 139: Diagnostic delays and healthcare access prior to colorectal cancer (CRC) diagnosis: Insights from young adult CRC survivors on promoting timely CRC screening. First Author: Oyedolapo Adedoyin Anyanwu, PhD, MS	Board C21	Abstract 152: Exploring fertility preservation decision-making among female AYAs with cancer: A qualitative study. First Author: Marcela Algave, BSN, MPhil
Board C9	Abstract 140: Regional peer-to-peer workshops: Building collaborative CAR T-cell therapy care models. First Author: Caroline Offit, MS	Board C22	Abstract 153: Inpatient diagnosis of screenable cancers: Associated factors and clinical outcomes. First Author: Jonathan Liles, MD
Board C10	Abstract 141: Leveraging a learning collaborative model to improve data sharing and breast cancer screening quality and outcomes in Southeastern Wisconsin. First Author: Kara Gavin	Board C23	Abstract 154: Healthcare access barrier burden and never-screening versus lapsed screening for colorectal cancer among US adults aged 45–75: A 2022 BRFSS analysis. First Author: Wamia Siddiqui, BS
Board C11	Abstract 142: Depression symptom severity and mental health utilization following breast cancer diagnosis. First Author: Constanza Tara Zamani, BA	Board D1	Abstract 155: Real-world outcomes of a diverse safety-net lung cancer screening program. First Author: Evan Garrad, MD
		Board D2	Abstract 156: Safety-net primary care access and screening-amenable cancer outcomes: A national county-level analysis. First Author: Canan Dilay Dirican, MD

Board D3	Abstract 157: Mitigating algorithmic bias in AI tools for early detection and care pathways: Equity-focused validation in diverse LMIC cohorts from Kyrgyzstan, MENA, and central Asia region. First Author: Mohd Faizan Siddiqui, MD, PhD	Board D17	Abstract 171: Trends in stage, treatment initiation, and survival disparity among individuals diagnosed with non-small cell lung cancer by rural-urban residency in the US. First Author: Vincent Nguyen, BS
Board D4	Abstract 158: Estimating county-level lung cancer screening prevalence using linked claims and multi-source data. First Author: Jennifer Leigh Lund, PhD, MSPH	Board D18	Abstract 172: Self-reported administrative burden in people with recently diagnosed breast cancer. First Author: Nora B. Henrikson, PhD, MPH
Board D5	Abstract 159: The influence of spatial access to primary care physicians (PCPs) and neighborhood marginalization on colorectal cancer (CRC) screening. First Author: Lu Wang, PhD	Board D19	Abstract 173: Advancing oncology advocacy through cross-state collaboration: A thematic analysis of multi-state policy town halls. First Author: Carolyn Trachtenbroit
Board D7	Abstract 161: Presenting symptoms and demographic factors associated with diagnostic delay in glioblastoma: A national survey of patients and caregivers. First Author: Jacob Ellen, MD, MS	Board D20	Abstract 174: Disparities in management of cancer-related pain: A systematic review. First Author: David Park, BS
Board D8	Abstract 162: Electronic cigarette use and cervical cancer screening adherence in a nationally representative sample. First Author: Hasan Obeidat, MBBS	Board D21	Abstract 175: Medicare Prescription Payment Plan (MPPP): Awareness, utilization, and barriers among people with cancer. First Author: Alexandra Katherine Zaleta, PhD
Board D9	Abstract 163: Impact of multidisciplinary navigation services on timely treatment initiation: A difference-in-differences analysis. First Author: Taylor McCready, MPH	Board D22	Abstract 176: Association between disability status, social vulnerability, and healthcare access among patients receiving cancer care in Ontario, Canada. First Author: Vidushi Swarup, MS
Board D10	Abstract 164: Do small (<50 gene) NGS panels capture all NCCN recommended biomarkers? An evaluation of 8 common cancers. First Author: John Leonard Fox, MD, MHA	Board D23	Abstract 177: Federal housing assistance, stage at diagnosis, treatment receipt and survival among Medicare beneficiaries <65 years with non-small cell lung cancer. First Author: Qinjin Fan, PhD
Board D11	Abstract 165: Do large (>200 gene) NGS panels capture all NCCN recommended genomic biomarkers? An evaluation of 8 common cancers. First Author: John Leonard Fox, MD, MHA	Board D24	Abstract 178: Reasons for delay in receipt of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer. First Author: Margaux Wooster, MD
Board D12	Abstract 166: Evolving demographic representation and patient-reported outcomes in landmark antibody-drug conjugate trials supporting FDA approvals, 2015-2026. First Author: Nitya Batra, MBBS	Board E1	Abstract 179: Real-world uptake, timeliness, and survival outcomes of consolidative immunotherapy (IO) for stage III non-small cell lung cancer (NSCLC). First Author: Chaewon Hwang, MD
Board D13	Abstract 167: Clinicopathological characteristics and treatment patterns of bladder cancer in a tertiary oncology centre in Sub-Saharan Africa. First Author: Emmanuel Temitope Andero	Board E2	Abstract 180: Insurance status as an independent predictor of survival in esophageal cancer: A SEER database analysis. First Author: Hisham Alsharif, MD
Board D14	Abstract 168: Practice infrastructure and barriers to metastatic cancer care: Landscape analysis of ICI and TKI delivery. First Author: Amina Tanweer, MD, BA, BS	Board E3	Abstract 181: Optimizing colorectal cancer NGS pathways: Quality gaps, workflow barriers, and digital/AI readiness. First Author: Luxiga Thanabalachandran, BSc
Board D15	Abstract 169: Improving on-time oral antineoplastic initiation at a safety-net oncology clinic: A mixed-methods QI study. First Author: Laura Burns Amin, MD	Board E4	Abstract 182: Safety and feasibility of outpatient (out-pt) ramp-up dosing of bispecific antibody (BsAb) therapy for cancer treatment at a US based community oncology practice. First Author: Ajeet Gajra, MD, FACP
Board D16	Abstract 170: Provider practice patterns and barriers to prescribing larlatamab for extensive stage small cell lung cancer. First Author: Yasmeen Murtaza, MD	Board E5	Abstract 183: Disparities in receipt of radiation therapy among patients with metastatic breast cancer and bone metastases: A population-based SEER analysis. First Author: Maryam Ali, DO

Board E6	Abstract 184: Global trends in testicular cancer mortality in the United States, 1999-2025: A 27-year retrospective analysis. First Author: Nagarjuna Keshapogu, MD	Board E20	Abstract 198: Development and informatics pipeline validation of the PROACT-RT early-warning system to mitigate weather-related oncology treatment disruptions. First Author: Katie Lichter, MD, MPH
Board E7	Abstract 185: Treatment access and disparities in chemotherapy utilization among very elderly patients with metastatic NSCLC: A SEER-based quality of care analysis. First Author: Maryam Ali, DO	Board E21	Abstract 199: Geography and equity in cancer care: Area deprivation and time to first appointment. First Author: Puneeth Indurlal, MD, MS, MBBS
Board E8	Abstract 186: Predictors of care at a high-volume center for AYAs with cancer in a statewide multipayer claims database. First Author: Jacob Newton Stein, MD, MPH	Board E22	Abstract 200: GVHD outcomes by donor match grade: 7/8 versus 8/8 unrelated donor HCT with post-transplant cyclophosphamide. First Author: Saad Abdul Kareem, MD, MBBS
Board E9	Abstract 187: Patient-reported financial sacrifice in the context of large-panel genomic tumor testing initiative. First Author: Jessica DiBiase, MPH	Board E23	Abstract 201: Characterizing patient decisions: Disparities in stigmatizing language use in cancer care electronic health records. First Author: Allison Dona, PhD
Board E11	Abstract 189: Insurance type and documented pancreatic enzyme replacement therapy claims among patients with pancreatic cancer and pancreatic exocrine insufficiency. First Author: Maksim Isachanka, MD	Board E24	Abstract 202: Temporal evolution and demographic stratification of CAR T-cell therapy utilization for multiple myeloma in the United States: Insights from a National Inpatient Cohort (2017–2022). First Author: Himil Mahadevia, MBBS
Board E12	Abstract 190: Time to treatment with lutetium-177-PSMA-617: A cross-system comparison of a VA and academic center. First Author: Nova Xu, MD	Board F1	Abstract 203: Temporal evolution and demographic stratification of CAR T-cell therapy utilization for diffuse large B-cell lymphoma in the United States: Insights from a National Inpatient Cohort (2017–2022). First Author: Himil Mahadevia, MBBS
Board E13	Abstract 191: Power outages and at-home cancer care continuity in the US: A county-level analysis of exposure risk. First Author: Zhiyuan Zheng, PhD	Board F2	Abstract 204: Trends in insurance coverage and stage at cancer diagnosis among disaggregated Asian American and Native Hawaiian/Pacific Islanders. First Author: James Fan Wu, MD
Board E14	Abstract 192: Variation in time to first appointment by insurance payer in community oncology practices. First Author: Anne Marie Rainey, MSN	Board F3	Abstract 205: Measures of socioeconomic position (SEP) in hospitalized patients with cancer. First Author: Anh B. Lam, DO, MBA
Board E15	Abstract 193: Impact of social determinants of health on genomic testing among patients with advanced/metastatic non-small cell lung cancer. First Author: Eileen Milien	Board F4	Abstract 206: Decomposing disparities in mammography screening by sexual orientation in the United States: The role of unmet health-related social needs. First Author: Hanwen Zhang, MS
Board E16	Abstract 194: Characterizing medication requests in a statewide cancer drug repository network: A YesRx pilot study. First Author: Emily R. Mackler, PharmD	Board F5	Abstract 207: Impact of cancer stage on racial disparities in time to treatment for breast, lung, and colon cancer patients. First Author: Andrea Yeung, BA
Board E17	Abstract 195: Trastuzumab treatment gap and its impact on HER2positive breast cancer care at Syria's main referral center. First Author: Ahmad Al-Bitar, MD	Board F6	Abstract 208: Trends in survival disparity among women diagnosed with breast cancer by rural-urban residency in the US. First Author: Jingxuan Zhao, PhD, MPH
Board E18	Abstract 196: Adjusted analysis of racial and socioeconomic disparities in time to treatment initiation among insured patients with newly diagnosed cancer in southern California. First Author: Robert Michael Cooper, MD	Board F7	Abstract 209: County-level rural-urban variation in NSCLC treatment and survival among Medicare beneficiaries. First Author: Tanvee Varma, MD
Board E19	Abstract 197: Environmental scan of oncology acute care clinics across NCI-designated comprehensive cancer centers. First Author: Manasa Kotamraju, BS	Board F8	Abstract 210: County-level jail incarceration rates and cancer stage at diagnosis, timely treatment initiation, and survival in the US. First Author: Jingxuan Zhao, PhD, MPH

Board F9	Abstract 211: Access to care and financial hardship by rurality in cancer survivors. First Author: Nova Yang, MSPH	Board F22	Abstract 224: An evaluation of GI oncology provider perspectives on care consistency across Moffitt's main campus (MCC) and ambulatory clinic sites (MACs). First Author: Kevin Avaiya
Board F10	Abstract 212: Temporal trends and correlates of stage at diagnosis, receipt of treatment, and survival among men newly diagnosed with breast cancer in the United States. First Author: Vincent Nguyen, BS	Board F23	Abstract 225: Survival among patients with colon cancer cared for in vertically integrated health care system in southern California. First Author: Robert Michael Cooper, MD
Board F11	Abstract 213: Intersectional identities of early onset colorectal cancer survivors in a nationally representative sample. First Author: Catherine Vander Woude	Board G1	Abstract 226: Intersecting risk paradigms: The impact of sex, urbanization, and nicotine exposure background on renal cell carcinoma mortality. First Author: Ronak Indurti, MBA
Board F12	Abstract 214: Racial, ethnic, and neighborhood-level disparities across the breast cancer care continuum: Time from abnormal imaging to biopsy and treatment initiation. First Author: Jacqueline Victoria Moses, BS	Board G2	Abstract 227: Socioeconomic and institutional disparities in preventable inpatient chemotherapy and radiation toxicities: A longitudinal analysis of national healthcare trends (2020–2023). First Author: Anuv Shevde
Board F13	Abstract 215: Association between insurance status, rurality, and quality of care in breast, colorectal, and lung cancer: Results from a statewide database in North Carolina. First Author: Tess Thompson, PhD	Board G3	Abstract 228: Federal housing assistance, stage at diagnosis, and survival in older adults with small cell lung cancer. First Author: Jordan Kaplan
Board F14	Abstract 216: Insurance-based disparities in patterns of care for brain metastases. First Author: Faith Ryu, BA	Board G4	Abstract 229: Upcoding of active cancer diagnosis in Medicare Advantage and traditional Medicare. First Author: Youngmin Kwon, PhD
Board F15	Abstract 217: Understanding competing mortality in patients with early-stage ER+ breast cancer. First Author: Chiara A. Wabl, MD	Board G5	Abstract 230: Hospital soft-tissue sarcoma volume and inpatient outcomes: A National Inpatient Sample analysis. First Author: Dayoung Ryu, MD, MPH
Board F16	Abstract 218: Racial and ethnic differences in treatment delays and recurrence among patients with head and neck cancer. First Author: Kamal Amirneni, BA	Board G6	Abstract 231: Widening racial and rural disparities in colorectal cancer mortality in Wisconsin: A population-based analysis, 1999–2020. First Author: Maxime Tindong, MD
Board F17	Abstract 219: Diverging global cancer mortality trajectories across socio-demographic development levels: A joinpoint analysis of GBD 2023 data, 1990–2023. First Author: Mobeen Sajjad, MBBS	Board G7	Abstract 232: Disparities in discharge outcomes among homeless versus low-income housed cancer patients: A National Inpatient Sample analysis. First Author: Dayoung Ryu, MD, MPH
Board F18	Abstract 220: Obesity-associated cancer mortality in the United States, 1999–2023: Diverging racial trends in the era of emerging GLP-1 receptor agonist therapy. First Author: Mobeen Sajjad, MBBS	Board G8	Abstract 233: Oncology in the crossfire: Mapping cancer care disruptions and responses in conflict zones of Sub-Saharan Africa. First Author: Eric Wah Sanji, MD
Board F19	Abstract 221: Real-world study of upfront genomic testing utilization in newly diagnosed non–small cell lung cancer. First Author: Kimberly J. Toomire, DO	Board G9	Abstract 234: Cumulative impact of social determinants of health on outcomes after immunotherapy for lung cancer: A real-world analysis. First Author: Amir Mehdizadeh-Shrifi, MD
Board F20	Abstract 222: Time to treatment initiation among patients with colorectal cancer and limited English proficiency. First Author: Sarah Marie Marini, MD	Board G10	Abstract 235: Mapping gastrointestinal cancer disparities across state of Virginia. First Author: Alisha Sharma, MD
Board F21	Abstract 223: Social deprivation, therapy intensity, and survival among AML patients with clinical and genomic features favoring lower-intensity therapy. First Author: Hae Lin Cho, MD	Board G11	Abstract 236: Integrating cardiovascular risk screening into a cancer screening program for underserved women in Connecticut: WISEWOMAN program experience. First Author: Beatriz Mella Soares Pessoa, MD

- Board G12 Abstract 237: Nationwide trend in colorectal cancer-related mortality among middle-aged and older adults with inflammatory bowel disease (IBD): A retrospective cohort study using CDC WONDER (1999-2024).**
First Author: Hina Ashraf, MBBS
- Board G13 Abstract 238: Race and the neoadjuvant-to-adjuvant pembrolizumab transition for early-stage triple-negative breast cancer in the KEYNOTE-522 era: A TriNetX US Collaborative Network analysis.**
First Author: Abhinav Anand Vayal Veetil, MD
- Board G14 Abstract 239: Equity gaps in NCCN concordant systemic therapy in metastatic breast and non-small cell lung cancer, 2014–2022: The PRISM study.**
First Author: Drew Neish
- Board G15 Abstract 240: Disparities in completing cancer care evaluation in patients seen in the same day/next day cancer program.**
First Author: Artem Oganessian, MD
- Board G16 Abstract 241: Prevalence and socioeconomic determinants of financial toxicity in patients undergoing breast cancer surgery in Canada: A cross-sectional study.**
First Author: Renata Sabelli
- Board G17 Abstract 242: Geospatial analysis of prostate cancer burden and social vulnerability across the state of Virginia.**
First Author: Alisha Sharma, MD
- Board G18 Abstract 243: Racial and ethnic differences in thyroid cancer histologic subtype distribution.**
First Author: Perisa Ashar, BS, MSc
- Board G19 Abstract 244: Prevalence and sociodemographic differences in documented health-related social needs among patients with renal cell carcinoma.**
First Author: Nana Shakhnazaryan
- Board G20 Abstract 245: Assessing barriers to genetic and tumor genome sequence testing in patients with metastatic stage IV breast cancer at an academic and public hospital in Georgia.**
First Author: Sydney M. Habert, MD
- Board G21 Abstract 246: Patient-reported needs by survey language among Hispanic/Latino adults with cancer.**
First Author: Abner Antonio Murray, MD, PhD
- Board G22 Abstract 247: Mid-year insurance churn and loss of insurance coverage among U.S. cancer survivors before and after the COVID-19 pandemic: A nationwide analysis.**
First Author: Krishna Sajeev, MBBS
- Board G23 Abstract 248: Reach, equity, and content performance of an oncologist-led bilingual social media cancer education initiative: Implications for quality cancer care.**
First Author: Maurice J. Berkowitz, MD, MS
- Board G24 Abstract 249: Patient navigation and healthcare access among breast cancer patients undergoing radiotherapy.**
First Author: Afua Ofori-Darko, BS
- Board H1 Abstract 250: Fertility counseling, preservation, and time to treatment in adolescents and young adults diagnosed with lymphoma.**
First Author: Chun Chao, PhD
- Board H2 Abstract 251: CAR T delivery and access in the U.S.: A cross-sectional survey of healthcare providers.**
First Author: Samantha Ammons, PhD
- Board H3 Abstract 252: Characterizing the use of fertility preservation among women with early-onset cancer in a nationwide electronic health record database.**
First Author: Ashlee Korsberg, MS
- Board H4 Abstract 253: Distant-stage incidence and all-stage mortality trends of cancers amenable to early detection by rural-urban status in the US, 1995-2022.**
First Author: Xuesong Han, PhD
- Board H5 Abstract 254: Improving food access and nutrition among food-insecure patients with cancer: A quality improvement pilot.**
First Author: Ashley Bowen, RD, MS, MSc
- Board H6 Abstract 255: Association of a standardized community health worker enrollment with cancer outcomes and clinical trial enrollment: A secondary case-control analysis.**
First Author: Oyepeju F. Abioye, MD, MSc
- Board H7 Abstract 256: A hidden driver of healthcare disparities: Geographic physician payment adjustments and socioeconomic deprivation.**
First Author: Puneeth Indurlal, MD, MS, MBBS
- Board H8 Abstract 257: Implementing a supportive care program to address transportation, financial, and emotional barriers in gynecologic oncology: Analysis of health system impact.**
First Author: Emily Meichun Ko, MD
- Board H10 Abstract 259: AYA-NAV intervention fidelity assessment: A needs navigation intervention for adolescents and young adults with cancer.**
First Author: Melissa P. Beauchemin, PhD, RN, NP
- Board H11 Abstract 260: Association of sociodemographic, geographic, and health factors with survival across randomized cancer trials.**
First Author: Joseph M. Unger, PhD
- Board H12 Abstract 261: Pharmacists optimizing oral anticancer agent time on therapy.**
First Author: Lydia L. Benitez, PharmD
- Board H13 Abstract 262: Association of social vulnerability with modifiable comorbidity burden and postoperative morbidity following colectomy for colon cancer.**
First Author: Zahra Shakarchi

Board H14	Abstract 263: State paid sick leave mandates and mortality from screening-amenable cancers among working-age adults in the United States. First Author: Canan Dilay Dirican, MD	Board J3	Abstract 381: Making patient values visible: Co-creating and piloting a values assessment tool (VAsT) for women with metastatic breast cancer. First Author: Lorinda A. Coombs, PhD, FNP, AOCNP, BC
Board H15	Abstract 264: A comparative analysis of non-responders and responders to health-related social needs items within a new patient intake survey in ambulatory oncology practice. First Author: Shiron Bagchi	Board J4	Abstract 382: Content validity of overtreatment and undertreatment in older adults with cancer: A multi-stakeholder qualitative study of new definitions. First Author: Ameya Sanyal
Board H16	Abstract 265: The geography of coverage: Payer mix differences across area deprivation index levels in community oncology. First Author: Altamash Rahman, MHA, MBA	Board J5	Abstract 383: Honest communication in an oncology patient population. First Author: Mubasher Jaffri, DO
Board H17	Abstract 266: Spatiotemporal changes of late-stage diagnosis of colorectal cancer in nonelderly adults after Medicaid expansion in New Hampshire. First Author: Christian Beck	Board J6	Abstract 384: Cancer information prescriptions as a scalable approach to decrease exposure to cancer treatment misinformation: Development and feasibility. First Author: Carma Bylund, PhD
Board H18	Abstract 267: Internal medicine resident continuity clinic and academic cancer center: Implementation of a collaborative model for primary care. First Author: Faraah Bekheet, MD	Board J7	Abstract 385: Surgeon gatekeeping and racial disparities in breast reconstruction referrals to plastic surgery. First Author: Faith Dickerson, MD
Board H19	Abstract 268: Evidence-based interventions to address rural cancer disparities: A systematic review and meta-analysis. First Author: Stephanie Keeling, MD	Board J8	Abstract 386: Changes in treatment persistency among patients who view personalized education upon treatment initiation. First Author: Davey B. Daniel, MD
Board H20	Abstract 269: A scalable multidisciplinary education model to improve advance care planning readiness across a large outpatient oncology network. First Author: Emily Percy, MSW	Board J9	Abstract 387: DISCO App: Feasibility and acceptability of an intervention to reduce the financial burden of cancer in a diverse patient population. First Author: Lauren M. Hamel, PhD, MBA
Board H21	Abstract 270: Housing assistance, care pathway complexity, and survival in colon and rectal cancer. First Author: S. M. Qasim Hussaini, MD, MS	Board J10	Abstract 388: Patient correlates of patient-provider communication and financial toxicity in Black and White patients with cancer. First Author: Lauren M. Hamel, PhD, MBA
Board H22	Abstract 271: Healthcare providers' personal cancer screening practices: A cross-sectional survey with general population comparison. First Author: Grace Gorecki, MD	Board J11	Abstract 389: A tethered patient-clinician educational initiative aligning immunotherapy education with patient-reported experience in non-melanoma skin cancer. First Author: Michael White, PhD
Board H23	Abstract 272: Trajectories toward elimination: Cervical cancer incidence trends among young U.S. women, 1999-2022, with projections through 2035. First Author: Aishwarya Ramesh, MD	Board J12	Abstract 390: Leveraging large language models (LLMs) to characterize serious illness conversations in advanced non-small cell lung cancer (aNSCLC). First Author: Aaron B. Cohen, MD, MSCE
Board H24	Abstract 273: Enhanced financial assistance intervention for unmet essential needs: A prospective pilot study for patients undergoing cancer treatment. First Author: Justin Michael Barnes, MD, MS	Board J13	Abstract 391: Comparative time toxicity of second-line regimens in relapsed or refractory follicular lymphoma. First Author: Charles J. Milrod, MD
Board J1	Abstract 274: Where legal help is missing: Mapping legal deserts to target oncology legal navigation and medical-legal partnerships. First Author: John R. Bassler, MS	Board J14	Abstract 392: A pilot study of large language model (LLM)-derived patient (pt)-friendly summaries derived from consultation notes: Analysis of accuracy, consistency, and readability. First Author: Charlotte Barker, DO
Board J2	Abstract 275: Bridging the primary care gap in oncology: Utilization and clinical outcomes of an embedded clinic model. First Author: Shreya Condamoor, MD, BS	Board J15	Abstract 393: Augmenting the comprehensiveness and quality of serious illness documentation using large language models. First Author: Justin Vinh

Board J16	Abstract 394: Rural is not a proxy: Values, trust, and healthcare engagement. First Author: Taylor Neilson, MD	Board K7	Abstract 408: Patient-centered approaches to mitigate administrative burden in cancer care. First Author: Bridgette Thom, PhD
Board J17	Abstract 395: Patient values in cancer care: Insights for shared decision-making. First Author: Emma Williams	Board K8	Abstract 409: Hodgkin lymphoma survivors' engagement in their long-term medical care. First Author: Rachel Murphy-Banks, MA
Board J18	Abstract 396: Countering cancer misinformation with a brief educational intervention in breast oncology. First Author: Annalise J. McDonald, MD, MBA	Board K9	Abstract 410: Using data workflow-based support to improve MyChart adoption and utilization. First Author: Maria Ferzoco, BS
Board J19	Abstract 397: Prognostic communication cues from patients and caregivers prior to immunotherapy initiation. First Author: Joely Anne Centracchio, BA	Board K10	Abstract 411: Barriers to team coordination for unplanned cancer admissions: A qualitative comparison of oncology and general hospitalist teams. First Author: Laiba Husain
Board J20	Abstract 398: Patient characteristics associated with discordant patient-oncologist expectations of physical function during treatment. First Author: Marielle Jensen-Battaglia, PhD, DPT	Board K11	Abstract 412: A national colorectal cancer navigation program for precision oncology and comprehensive support. First Author: Kimberley Lynn Newcomer, BS
Board J21	Abstract 399: Insights from artificial intelligence (AI)-powered patient navigation: Proactive identification of practical and emotional needs for people with cancer. First Author: Nitya Naomi Lorber, BS	Board K12	Abstract 413: Participant adherence in a lung cancer screening (LCS) program in a non-smoking population. First Author: Jaimie Lin Bell, DNP, ANP-BC
Board J22	Abstract 400: Will AI widen the gap? Exploring lung cancer patient perceptions of AI. First Author: Chelsea Ducille, PhD, MSPH	Board K13	Abstract 414: Characterizing care fragmentation of pancreatic cancer care co-management: continuity challenges in inter-system care delivery. First Author: Amol Narang, MD
Board J23	Abstract 401: Public interest in ivermectin and fenbendazole for cancer following a high-profile podcast release: A Google trends analysis. First Author: Nitya Naomi Lorber, BS	Board K14	Abstract 415: Evaluation of aromatherapy and patient-reported calmness and queasiness in oncology infusion settings. First Author: Mandie Hall, MBA, MSN, RN
Board K1	Abstract 402: Hope for a cure: Exploratory analysis of prognostic awareness of people living with advanced lung cancer. First Author: Chelsea Ducille, PhD, MSPH	Board K15	Abstract 416: PRO results from the Beamion LUNG-1 trial in treatment-naïve patients with HER2-mutant advanced NSCLC. First Author: Joshua K. Sabari, MD
Board K2	Abstract 403: Oncoplastic breastconserving surgery utilization among eligible premenopausal women: A qualitycare review at a tertiary academic center. First Author: Katie Kenny, BS	Board K16	Abstract 417: Longitudinal PROMIS10 global health scores as independent prognostic values in advanced sarcoma. First Author: Hisham Alsharif, MD
Board K3	Abstract 404: Beyond contact days: Assessing measurement and communication preferences for clinical trial time costs. First Author: Hannah Rebecca Abrams, MD	Board K17	Abstract 418: Patient- and clinician-informed development of an Epic-integrated ePRO tool to support CDK4/6 inhibitor persistence. First Author: Michelle Caetano, PharmD
Board K4	Abstract 405: Patient and provider perspectives on barriers to timely breast cancer diagnosis and care: A mixed-methods study. First Author: Jacqueline Victoria Moses, BS	Board K18	Abstract 419: Association between perioperative patient satisfaction and post-discharge quality of life in patients with breast cancer undergoing elective surgery: A longitudinal study in Japan. First Author: Taiga Komatsu, MD
Board K5	Abstract 406: Implementation of e-consults for benign hematology consults to improve access for hematology/medical oncology in-office consults. First Author: Alexandra Buczek, MSc	Board K19	Abstract 420: Patient-reported outcome completion rates among cancer patients enrolled in an employer-sponsored care navigation program. First Author: Stephen Speicher, MD
Board K6	Abstract 407: A proactive approach to reducing no-shows in a testicular cancer surveillance clinic at a large comprehensive cancer centre. First Author: Andrea Ipanaque	Board K20	Abstract 421: Patient preferences in the treatment of human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (eBC). First Author: Marvin Nguyen, PharmD, MS

Board K21	Abstract 422: Patient-reported sexual health outcomes and quality of life in younger versus older breast and gynecologic cancer survivors. First Author: Amelie Foumena Nkodo, MD, MS	Board L10	Abstract 435: Evaluating the impact of immunotherapy on quality of life in cancer patients: A single-center study. First Author: Samhitha Gundakaram, MBBS
Board K22	Abstract 423: Time toxicity in high grade glioma patients within an integrated healthcare system. First Author: Bryant Chee, DO	Board L11	Abstract 436: Conceptualizing time toxicity in cancer care: A qualitative study to inform measure development. First Author: Erin Mary Bange, MD
Board K23	Abstract 424: Humanistic burden of melanoma recurrence after definitive surgical resection: Patient and caregiver perspectives from the United States. First Author: Salome Samant	Board L12	Abstract 437: "More feet on the ground:" When non-clinical staff are needed for ePRO-enabled remote symptom monitoring implementation. First Author: Tanvi Padalkar, BS, MA
Board K24	Abstract 425: Legal advocacy for cancer patients and caregivers (LEGACY CARE): A pilot clinical trial. First Author: Kendall Lin, BS	Board L13	Abstract 438: Needs assessment for cancer survivors and implications for cancer survivorship care delivery and research. First Author: Niharika Dixit, MD, FASCO
Board L1	Abstract 426: Association between health literacy and sustained patient engagement with ePRO-based remote symptom monitoring in cancer care. First Author: Sandra C. Olisakwe, MSPH	Board L14	Abstract 439: Patient-reported measure collection in NCI Community Oncology Research Program (NCORP) cancer care delivery research studies: Barriers and recommendations. First Author: Victor Basil, PhD
Board L2	Abstract 427: Longitudinal changes in patient-reported quality of life (QOL) and hope among early phase cancer clinical trial (EPCT) participants. First Author: Debra Lundquist, PhD, RN	Board L15	Abstract 440: Leveraging patient experience data to improve wayfinding across a comprehensive cancer center. First Author: Maria Ferzoco, BS
Board L3	Abstract 428: Patients' attitudes toward artificial intelligence across the cancer care continuum: A mixed-methods study. First Author: Allison Lipitz-Snyderman, PhD	Board L16	Abstract 441: Longitudinal changes in prognostic awareness (PA) among early phase cancer clinical trial (EPCT) participants. First Author: Kaitlyn Lynch, MS
Board L4	Abstract 429: A qualitative study to explore the patient experience of living with early breast cancer and perspectives on survivorship. First Author: Rebecca Sugarman	Board L17	Abstract 442: Population-level patient perspectives on environmental threats and environmentally sustainable cancer care in a rural NCI catchment area. First Author: Katie Lichter, MD, MPH
Board L5	Abstract 430: Total time toxicity associated with treating patients with previously treated endocrine refractory HR+/HER2- metastatic breast cancer (mBC). First Author: Marvin Nguyen, PharmD, MS	Board L18	Abstract 443: Using artificial intelligence (AI) to enhance collection of patient natural language adverse events (AEs) post-ambulatory cancer surgery. First Author: Jennifer Cracchiolo
Board L6	Abstract 431: Improving data capture of the patient experience for young adults with cancer: A randomized controlled trial of precision electronic patient-reported outcomes in community-based oncology practices (ECOG-ACRIN EAQ202). First Author: John M. Salsman, PhD	Board L19	Abstract 444: Embedding oncology patient navigators within ePRO workflows to support patient engagement. First Author: Danielle Julian, BSc, BSN, RN
Board L7	Abstract 432: Characterizing social determinants of health beyond material hardship in a tertiary radiation oncology population: A prospective single-institution survey. First Author: Hannah In Park, BS	Board L20	Abstract 445: From patient needs to clinical action: Implementing scalable, customizable ePRO-driven supportive care in head and neck cancer. First Author: Eden Brauer, PhD, RN, MSN
Board L8	Abstract 433: Time to encounter: Using predictive modeling to improve communication experience in ambulatory oncology. First Author: Jessica Bechtel, MHA	Board L21	Abstract 446: Optimizing patient self-management and care clarity in hepatocellular carcinoma: A comparative evaluation of 4R Care Sequence plans. First Author: Maen Abdelrahim, MD, PhD, PharmD
Board L9	Abstract 434: Quality of life and patient-reported symptomatic toxicity with radiotherapy plus durvalumab versus cetuximab in cisplatin-ineligible head and neck cancer: NRG-HN004. First Author: Minh Tam Truong, MBBS, MBA	Board L22	Abstract 447: Purposeful rounding to reduce falls and improve inpatient experience. First Author: Kelly Eng, MHA

- Board L23** **Abstract 448: Patient-reported outcomes and quality-of-life measures in a high-impact oncology journal: Insights from the *Journal of Clinical Oncology*.**
First Author: Kendra Wilson, DO
- Board L24** **Abstract 449: Effect of group community health worker–led advance care planning education on advance care planning, satisfaction, palliative care, hospice, and patient activation: Results from a randomized clinical trial.**
First Author: Olivia Viruet Quintero, BS
- Board M1** **Abstract 450: Pitch the PAC: Integrating lived experiences of diverse patient advocates into earliest oncology trial development.**
First Author: Anne Marie Mercurio, BA
- Board M2** **Abstract 451: Disability-related experience in oncology: Results of a novel disability-focused patient experience survey.**
First Author: Dennis Adey Jr., BA
- Board M3** **Abstract 452: Impact of federal vaccine policy changes and ongoing debate on cancer patients and survivors’ attitudes toward vaccines.**
First Author: Cassandra E. Welch
- Board M4** **Abstract 453: Who do patients trust? Cancer information-seeking across the rural–urban divide.**
First Author: Payton Markley, MD
- Board M5** **Abstract 454: “I’m putting my life in their hands”: A qualitative analysis of adolescent and young adult oncology patient perceptions of trust in their providers.**
First Author: Molly Ream, PhD, BA
- Board M6** **Abstract 455: Addressing the training gap in oncology on sexual health: Development and pilot test of a virtual, group-based course for hematology-oncology fellows.**
First Author: Jennifer B. Reese, PhD
- Board M7** **Abstract 456: Symptom burden, financial distress, and disease-specific patterns in ambulatory palliative oncology: A cross-sectional analysis using the Edmonton Symptom Assessment System.**
First Author: Mellar P. Davis, MD
- Board M8** **Abstract 457: Clinical management and alert burden associated with severe symptom alerts in a pilot randomized trial of a cancer pain self-management app.**
First Author: Elizabeth Tchitchkan, BA, BS
- Board M9** **Abstract 458: Using real-world data to characterize distinct experiences of and risk factors for worse cancer-related cognitive impairment.**
First Author: Rachel A. Pozzar, PhD, FNP
- Board M10** **Abstract 459: The burden of genitourinary syndrome of menopause and barriers to treatment in a safety-net breast cancer population.**
First Author: Ananya Murthy, BS
- Board M11** **Abstract 460: Reporting symptoms of potential immune-related adverse events in people with cancer treated with checkpoint inhibitors: A qualitative examination of patient-reported outcomes in the INSITE study.**
First Author: Sharon McCoy, MS
- Board M12** **Abstract 461: Distress in pregnancy-associated breast cancer: A case-control study.**
First Author: Nikki C. Daniels, BA
- Board M13** **Abstract 462: Fezolinetant for management of vasomotor symptoms (VMS) in patients with breast cancer taking endocrine therapy.**
First Author: Norah Lynn Henry, MD, PhD, FACP, FASCO
- Board M14** **Abstract 463: Statin exposure and oxaliplatin-induced peripheral neuropathy in stage II–III colon cancer: A dose-stratified, propensity-matched analysis.**
First Author: Mohamed Jimale, BS
- Board M15** **Abstract 464: Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)–based therapy in metastatic renal cell carcinoma (mRCC).**
First Author: Kaela Makins, PhD
- Board M16** **Abstract 465: Impact of dietitian intervention (DI) on treatment tolerance during chemoradiation (CRT) in a community-based oncology practice.**
First Author: Ria Badgujar, BS
- Board M17** **Abstract 466: Patterns of treatment-related adverse events and treatment discontinuation in phase III oncology clinical trials.**
First Author: Hannah Pearl, BS
- Board M18** **Abstract 467: The association between ePRO symptom reporting and prescriptions for supportive care medications.**
First Author: Michael J. Hassett, MD, MPH, FASCO
- Board M19** **Abstract 468: Integrating longitudinal patient symptom monitoring and opioid prescribing patterns in a multi-provider context.**
First Author: Linnea T. Olsson, PhD, MSPH
- Board M20** **Abstract 469: Characterization of adverse and favorable risk patients with acute myeloid leukemia (AML) receiving intense and less intense treatment using electronic patient reported outcomes (ePRO).**
First Author: Omer Hassan Jamy, MD
- Board M21** **Abstract 470: Low-risk breast cancer survivors’ expectations for symptom discussions during oncology follow-up.**
First Author: Jessica R. Schumacher, PhD
- Board M22** **Abstract 471: A mixed methods analysis of young breast cancer survivors’ symptom self-monitoring and management.**
First Author: Timiya S. Nolan, PhD, ANP-BC, FAAN, BSN, MSCE

- Board M23 Abstract 472: Prevalence and predictors of cachexia in advanced urothelial carcinoma (aUC) patients receiving enfortumab vedotin (EV)-based therapy.**
First Author: George Zhang, BA
- Board N1 Abstract 473: Evaluating longitudinal concordance in the perceived importance of fertility maintenance between premenopausal women with cancer and their providers: ECOG-ACRIN E1Q11.**
First Author: Julia Stal, PhD
- Board N2 Abstract 675: Development and validation of an agentic approach to care gap detection for hereditary cancer testing.**
First Author: Chelsea Kendall Osterman, MD
- Board N3 Abstract 676: FutureWise: A pilot of a digital, AI-enabled priming nudge to promote advance care planning in advanced cancer.**
First Author: Henry Kazunaru Litt, MD
- Board N4 Abstract 677: Implementation of an electronic frailty index for prospective frailty detection and management in an oncology clinic.**
First Author: Clark DuMontier, MD, MPH
- Board N5 Abstract 678: HEAT-ONC: Development of a point-of-care decision support tool for climate-resilient and low-carbon care in oncology practice.**
First Author: Oyepeju F. Abioye, MD, MSc
- Board N6 Abstract 679: A conversational, multilingual, on-device patient-reported outcome instrument for quality of life and supportive-care triage in oncology: The Comprehensive Cancer Quality of Life Index (CCQOL-I)—Administration feasibility and a pre-registered validation protocol.**
First Author: Chad Markey, MD
- Board N7 Abstract 680: Impact of an automated secure-chat alert on timely antibiotic ordering for febrile neutropenia.**
First Author: Jerry Kong, MD, BS
- Board N8 Abstract 681: Effect of EMR-integrated interventions on gaps in guideline concordant biomarker testing rates in early-stage NSCLC: A community oncology pilot.**
First Author: Haley Spitz
- Board N9 Abstract 682: Communicating options for advanced breast cancer support and treatment (COAST): Developing a decision support tool.**
First Author: Laura C. Pinheiro, PhD, MPH
- Board N10 Abstract 683: Forecasting radiotherapy workload and machine capacity to support timely treatment initiation in a resource-constrained multi-platform facility.**
First Author: Julia Rebecca Posadas
- Board N11 Abstract 684: Utilization of Breast Cancer Index (BCI) in early stage breast cancer patients (pts) in a community-based practice.**
First Author: Ishaan Shah, BS
- Board N12 Abstract 685: Understanding oncologists' use of artificial intelligence in the clinical setting: A field medical study.**
First Author: Venky Kashi, PhD
- Board N13 Abstract 686: Effect of AI-powered clinical decision support with peer collaboration on guideline-concordant oncology care in US community practice: A platform analysis using Konsuld.**
First Author: Stefan Gluck, MD, PhD
- Board N14 Abstract 687: Patient-reported tobacco use integrated with EHR clinical decision support for lung cancer screening in primary care.**
First Author: Mary Elizabeth Cooley, PhD
- Board N15 Abstract 688: Patient and clinician factors influencing the effectiveness of nudge strategies to improve timely completion of comprehensive molecular testing in lung cancer.**
First Author: Anne Montgomery, PhD, MSc
- Board N16 Abstract 689: iNUDGE: Integration of liquid biopsy based NGS in newly diagnosed NSCLC—Results from a stepped wedge cluster randomized control trial (SW-CRT).**
First Author: Anthony O. Martella, MS
- Board N17 Abstract 690: Reducing variation in infusion scheduling through a role-based AI enabled decision support tool.**
First Author: Cassie McNees, BA
- Board N18 Abstract 691: Implementation and early operational outcomes of a national cancer second-opinion program across an integrated health system.**
First Author: Tatjana Kolevska, MD
- Board N19 Abstract 692: Exercise and physical activity interventions in hepatocellular carcinoma survivorship: A systematic review.**
First Author: Jay Patel, MD
- Board N20 Abstract 693: Technology experience of older adults with cancer during a telehealth-based interventional clinical trial.**
First Author: Emily Nguyen
- Board N21 Abstract 694: Resident physician-answered emergency oncology telephone service at a lower-middle-income country cancer center: Assessment of call appropriateness, hospital visits, and patient out-of-pocket cost.**
First Author: Zaigam Ismail, MBBS, FCPS, MRCP
- Board N22 Abstract 695: Beyond the audiovisual visit: Audio-only telemedicine use among patients with cancer.**
First Author: Charlotte Diane Malling
- Board N23 Abstract 696: Implementation and evaluation of a nurse-led survivorship care program using teleconsultation: A pilot feasibility study.**
First Author: Smita Kayal, MD
- Board N24 Abstract 697: Air quality, guideline-concordant care, and survival among patients with non-small cell lung cancer.**
First Author: Nicole E. Caston, PhD, MPH

Board P1	Abstract 698: Real-world outcomes of definitive radiotherapy for muscle-invasive bladder cancer: A single-center experience. First Author: Alshaymaa Abdelghaffar, PhD	Board P13	Abstract 710: Real-world outcomes and immune-related adverse events in Canadian patients with non-small cell lung cancer receiving neoadjuvant platinum-based chemotherapy and nivolumab. First Author: Daniel Wang, BSc
Board P2	Abstract 699: Treatment patterns following next-generation sequencing in U.S. Veterans with metastatic cancer across social determinants of health. First Author: Kaelyn Nannini, MS	Board P14	Abstract 711: Incidence of antibody drug conjugate (ADCs) treatment-related events among solid-tumor patients: A real-world claims database analysis. First Author: Sara M. Tolaney, MD, MPH, FASCO
Board P3	Abstract 700: Quality and value in remote oncology expert review: Recommendation patterns, adoption, and cost implications. First Author: Debra Wong, MD	Board P15	Abstract 712: Artificial intelligence in oncology practice: National perspectives on adoption, confidence, and implementation readiness. First Author: Teresa van Oort, MHA, MSW
Board P4	Abstract 701: Treatment patterns among Medicare beneficiaries with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC) during 2020-2024. First Author: Ronald C. Chen, MD, MPH, FASCO	Board P16	Abstract 713: A comparison of side effects of NALIRIFOX vs. FOLFIRINOX in pancreatic cancer using real-world evidence. First Author: Julia Berg, MD
Board P5	Abstract 702: Treatment patterns among US patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC) during 2021–2024: Retrospective cohort study using the IQVIA database. First Author: Ronald C. Chen, MD, MPH, FASCO	Board Q1	Abstract 714: Clinical impact of a precision oncology review workflow for actionable genomic findings. First Author: Jennifer Le Uyen Vu, MD
Board P6	Abstract 703: Real-world clinical outcomes among patients with EGFR-mutated (Ex19del/L858R) metastatic NSCLC treated at City of Hope with osimertinib monotherapy by TP53 alteration status. First Author: Stephen B. Gruber, MD, PhD	Board Q2	Abstract 715: Patient-centered trial design in phase III advanced cancer trials: Control arm and endpoint selection, 2015–2024. First Author: Vaishali Aggarwal, MBBS
Board P7	Abstract 704: Real-world treatment patterns, outcomes, and burden of early progression in small cell lung cancer (SCLC) in the US. First Author: Su Zhang	Board Q3	Abstract 716: Real-world treatment pathways and outcomes in metastatic NSCLC across Spanish hospitals: Insights from the ECO-ARWEN study. First Author: Alvaro Rogado, BBA
Board P8	Abstract 705: Real-world dosing patterns of cEGFRm non-small cell lung cancer patients receiving amivantamab plus chemotherapy in the second or third line setting. First Author: Alexander I. Spira, MD, PhD, FACP, FASCO	Board Q4	Abstract 717: Development of a self-assessment quality improvement tool for small cell lung cancer. First Author: Bianca Alvarez, MPH
Board P9	Abstract 706: Assessment of a comprehensive hereditary cancer education program for advanced practice providers in the community oncology setting. First Author: Kate Principe, MS, CGC	Board Q5	Abstract 718: LLM translation of GI oncology cancer therapy education materials: Automated MQM evaluation across four platforms. First Author: Karthik Ramesh, MD
Board P10	Abstract 707: Healthcare resource utilization (HCRU) in patients (Pts) with platinum-resistant ovarian cancer (PROC) treated with mirvetuximab soravtansine (MIRV) or chemotherapy (Chemo). First Author: John Chan	Board Q6	Abstract 719: Application to identify potential patients and provide decision data for a novel PD-1/PDL-1 inhibitor clinical trial. First Author: Vincent Edgar Reyes Jr., MD, MMM
Board P11	Abstract 708: Incidence and trends in venous thromboembolism in the post-COVID era: Analysis of high-VTE risk vs intermediate-VTE risk malignancies using real-world data. First Author: Chinenye M. Okafor, MD, MPH	Board Q7	Abstract 720: From digital patient navigation to shared care: A clinician-facing platform to bridge academic-community oncology fragmentation. First Author: Govind Warriar, MD, MPH
Board P12	Abstract 709: Efficacy of in-person versus virtual recruitment methods for oncology clinical trials. First Author: Noa Waisman	Board Q8	Abstract 721: Development, feasibility, and acceptability of the ASCO Assessment for Survivors of Cancer (ASC) Tool: A multi-site quality improvement project. First Author: Niharika Dixit, MD, FASCO
		Board Q9	Abstract 722: Use of an electronic medical record (EHR) embedded geriatric screening and multidisciplinary triage system to enhance care of older adults with cancer. First Author: Elizabeth R. Kessler, MD

Board Q10	Abstract 723: Addressing the gap in genetic screening post-test management: A technology-enabled navigation approach. First Author: Danelle Johnston, MSN, OCN, RN	Board R9	Abstract 735: AI-powered real-time clinical documentation in oncology and internal medicine: A pilot study of automated SOAP note. First Author: Parth Kaushik, MS
Board Q11	Abstract 724: Onco-Guard AI: Proactive symptom clarification and safety-aware alert routing for remote oncology toxicity surveillance. First Author: Xiaozhong Liu	Board R10	Abstract 736: Ambient listening/AI technology and oncology documentation: Impact measured in a comprehensive cancer center. First Author: Katy E. French, MD
Board Q12	Abstract 725: Patient and provider-directed perspectives on the development of a natural language processing (NLP)-enabled symptom reporting tool for patients with head and neck cancer. First Author: Brenton S Halsey III, MD, MA	Board R11	Abstract 737: Automating inpatient mortality reviews. First Author: Dhruvkumar Patel, MS
Board Q13	Abstract 726: Impact of OP35 events on 30-day readmissions: Implications for symptom management and avoidable hospital utilization. First Author: Valerie Pracilio Csik, MPH	Board R12	Abstract 738: Neurosymbolic AI-augmented prescreening for a national phase III prostate cancer trial: A prospective cohort study of screening efficiency and diversity. First Author: So Hee Ahn
Board R1	Abstract 727: Real-world use of patient-centered artificial intelligence (AI) in oncology outside business hours: Filling the care gap at scale. First Author: Erin Landis	Board R13	Abstract 739: Implementation of an AI-enabled clinical workflow augmentation platform in community oncology: Early effects on clinical operations, documentation quality, and administrative burden. First Author: Larry Edward Bilbrey Sr., BS
Board R2	Abstract 728: Does financial fragility at diagnosis impact symptomatology and physiologic response to cancer treatment? A pilot study. First Author: Karma L. Kreizenbeck, BA	Board R14	Abstract 740: The impact of a domain-specific harness on large language model evaluations of medical necessity in oncology. First Author: Basit Iqbal Chaudhry, MD, PhD
Board R3	Abstract 729: Reducing failures of current real-world active surveillance schedules in early stage germ cell tumors: Role of new germ cell cancer biomarker—Mir371. First Author: Lucia Nappi, MD, PhD, FRCPC	Board R15	Abstract 741: Care-delivery burden of novel hematologic cancer therapies: A label-based implementation index. First Author: Sri Pranita Cherukuri, MPH, MBBS
Board R4	Abstract 730: Crossing the blood–brain barrier: Temporal trends and disparities in mortality from breast cancer with brain metastasis among postmenopausal women in the United States, 1999–2025. First Author: Mahrukh Mahrukh	Board R16	Abstract 742: Selecting an ambient AI documentation platform in community oncology: A structured evaluation framework for vendor selection and implementation. First Author: Larry Edward Bilbrey Sr., BS
Board R5	Abstract 731: Effect of ePRO symptom-based remote therapeutic monitoring (RTM) on time on therapy in patients treated with immune checkpoint inhibitors for metastatic lung cancer. First Author: Michael A. Kolodziej, MD	Board S1	Abstract 743: Implementation of an electronic clinical pathway for endocrine immune-related adverse events in patients receiving immune checkpoint inhibitors. First Author: Megan Spradlin, PA-C
Board R6	Abstract 732: LLM-assisted identification of baseline predictors of cardiovascular immune-related adverse events in ICI-treated lung cancer: A retrospective real world study. First Author: Kush Gupta, MBBS	Board S2	Abstract 744: Identifying gaps in hereditary germline testing for breast cancer patients through AI-driven clinical decision support. First Author: Manaswini Krishnakumar, MD
Board R7	Abstract 733: Development, validation, and deployment of a point-of-care risk-stratification system to guide proactive outreach for emergency department visits in community oncology: A quality improvement initiative. First Author: Kevin C. Wood, MD	Board S3	Abstract 745: Implementation of data-driven poor prognosis nodes within an oncology clinical pathways system. First Author: Belinda Desravines, MS
Board R8	Abstract 734: Administrative and clinical burden in community oncology intake: A retrospective evaluation of AI-assisted referral processing and clinician-in-the-loop (CITL) clinical summarization. First Author: Christine E. White, BSN, OCN, RN	Board S4	Abstract 746: A quality improvement initiative to strengthen documentation compliance for inpatient restraint utilization in a cancer center. First Author: Saima Awan, MBA
		Board S5	Abstract 747: Oncologist evaluations of large language models for lay summarization of clinical notes. First Author: Eric Blackstone, PhD

Board S6	Abstract 748: Evaluation of goals-of-care documentation quality in oncology using a large language model. First Author: Dhruvkumar Patel, MS	Board S14	Abstract 756: Computationally detected pancreatic masses: Opportunities for closed-loop workflows across a large integrated health system. First Author: Murtuza Hassan
Board S7	Abstract 749: The impact of AI on clinical decision making in healthcare teams: A qualitative study of a randomized controlled study. First Author: Farnam Mohebi	Board S15	Abstract 757: The effect of remote work and AI tool use for treatment planning on burnout and the perception of a healthy work-life balance. First Author: Ajay Dubey, MD, MPH
Board S8	Abstract 750: Longitudinal trends in patient portal utilization among oncology patients: An interrupted time series analysis of the effects of COVID-19 and the 21st Century Cures Act. First Author: Roman C. Kouznetsov, BS	Board S16	Abstract 758: Addressing gaps in breast cancer risk prediction scores in the electronic health record. First Author: Michelle Pistner Nixon, PhD
Board S9	Abstract 751: From manual to AI-assisted: Improving infusion scheduling in a high-volume cancer center. First Author: Kian Tehranchi, MD	Board T1	Abstract 759: The emerging role of large language models in oncology care delivery: A bibliometric and thematic analysis. First Author: Shoubhit P. A. Nair
Board S10	Abstract 752: Real-world evidence from an implemented, patient-centered artificial intelligence (AI) to address social determinants of health (SDOH) and Quality Oncology Practice Initiative (QOPI) measures to close care gaps. First Author: Douglas W. Blayney, MD, FASCO	Board T2	Abstract 760: Privacy preserving clinical trial navigation for KRAS driven cancers. First Author: Terri Conneran, BS
Board S11	Abstract 753: AI-assisted navigation (iNav) to improve diagnosis-to-treatment interval and research enrollment in patients with suspected pancreatic cancer. First Author: Siva Poojitha Madala, MPH	Board T3	Abstract 761: Clinical AI adoption and safety evaluation among hospital-based cancer programs in the United States. First Author: Charles Jiang, MD, MPH
Board S12	Abstract 754: Beyond fit vulnerable frail: Using unsupervised machine learning to identify vulnerability phenotypes in older adults with cancer. First Author: Charlotte Zuber, MD	Board T4	Abstract 762: PR-DOC trial: Remote wearable monitoring and enhanced care management in oncology. First Author: Maya Lubarsky, MD, MPH
Board S13	Abstract 755: Large language models in qualitative analysis of clinical ethics consultations in oncology. First Author: Alok Deshane, MD, MA	Board T5	Abstract 763: Accelerometer profiles of 24-hour movement behaviors in CPS-3: Associations with menopausal status and cancer history. First Author: Lauren C. Bates-Fraser, PhD, MA
		Board T6	Abstract 764: Wearable step and activity-rhythm metrics for frailty classification in adults aged 50 and older with cancer in the NIH All of Us research program. First Author: Kenan S. Najjar, BA